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1.4 Abstract 
 
Classical galactosemia is caused by deficiency of the enzyme galactose-1-phosphate 
uridyltransferase (GALT). The reason for the deficiency is a specific gene mutation causing 
an amino acid exchange near the active site of the enzyme. The turnover rate of the enzyme is 
therefore more than thousand-fold decreased. Dietary galactose uptake, for instance drinking 
milk, is followed by an intracellular stress response. The co-substrate of the GALT galactose-
1-phosphate accumulates intracellularly and disturbs carbohydrate-dependent metabolic 
pathways and presumably the Leloir pathway. The Leloir pathway supplies UDP-galactose 
and UDP-glucose for glycosylation of proteins and lipids. UDP-galactose incorporation is 
necessary, for example, to build up complex-type antennae of N-glycans on glycoproteins. It 
was supposed that, if the Leloir pathway is affected, the N-glycosylation, especially 
galactosylation in complex-type chains, will be affected. For examination of changes in 
glycosylation patterns mass spectrometric glycomics methods were chosen as most suitable. 
The N-linked carbohydrate branches were detached by PNGaseF digestion and analyzed 
applying matrix-assisted laser ionization mass spectrometry after glycan methylation. For 
examination of glycan pattern changes we isolated vesicles, mainly exosomes from urine of 
galactosemia patients as easily accessible source of epithelial membranes, and compared the 
N-glycome with the corresponding samples of healthy controls. The comparison of the mass 
spectra reveals a dramatic glycosylation shift from prevalent high-mannose-type N-glycans 
found in healthy controls towards complex-type glycosylation in patients. The estimated ratio 
of the amounts of high-mannose-type versus complex-type was about 3:1 respecting the 
healthy control samples. Especially the N-glycans that either carry five or six mannoses were 
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detected as most abundant. In contrast the ratio for patients shifted to nearly 1:1 towards 
complex-type glycosylation. The most abundant complex-type glycans from exovesicular 
membranes of GALT-deficient patients were of bi-antennary structure, terminal disialylated 
and without core fucosylation. Glycans with higher antennary branching were found in 
marginal amounts, only. The observed glycosylation shift can be regarded as a new finding 
and it may be assumed that not only secreted proteins like transferrin become dysglycosylated 
in galactosemia. Furthermore, cell surface located glycoproteins, especially receptors, were 
affected. Changes in glycosylation patterns were suspected to be responsible for missorting of 
glycoproteins especially for glyco-receptors like the EGFR (epidermal growth factor receptor) 
which is regularly expressed at apical membranes of epithelial cells. 
Quantitative and qualitative alterations of membranous exosomal glycoproteins indirectly 
provide information of alterations at the cell membrane. To study alterations of 
glycoproteoms, especially glyco-receptors, in exosomal lipid rafts, an iTRAQ (isobaric tags 
for relative and absolute quantitation) labeling was chosen as suitable for a quantitative in 
vitro experiment based on urinary exosomes. Four different individual samples were selected: 
two galactosemic samples (from patients showing drastic shifts from high-mannose to 
complex-type N-glycosylation) and two healthy controls. The samples were labeled with the 
isobaric tags, mixed and analyzed by offline nano-LC MALDI-MS/MS (liquid 
chromatography-matrix-assisted laser desorption-ionization-mass spectrometry). Although 
EGFR was not detected in the experiment we found strongly increased amounts of N-
glycoproteins and some receptors associated with galactosemic exosomes: tyrosine-protein 
kinase receptor UFO, zinc-alpha-2-glycoprotein (ZA2G, MHC I -family) and aminopeptidase 
N (CD13), to name some. The cubilin receptor and megalin were also found. They dimerize 
to form the megalin-cubilin-complex and are responsible for protein reabsorption at the 
proximal tubulus of the nephritic kidney. This cubilin receptor was detected in a further 
experiment to be one of the major differences between samples of galactosemia patients and 
control persons.  
Finally, the iTRAQ experiment revealed another unexpected result. The samples of the 
galactosemia patients contained increased amounts of serum proteins, in particular N-
glycoproteins. A large variety of immunoglobulins were found increased; further albumin, 
fetuin, transferrin and many more. All together these results strongly suggest renal failure for 
these examined galactosemic patients.  
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Biopsy is usually the most common method to detect renal diseases. The examination of 
urinary exosomal samples therefore possibly represents a new diagnostic method to detect 
renal failure without surgical intervention. 
 
2. Introduction 
2.1.1 Galactose-1-phosphate uridyltransferase (GALT) 
2.1.1.1 GALT 3D structure 
 
Classical galactosemia is caused by a profound deficiency of galactose-1-phosphate 
uridyltransferase (GALT; EC 2.7.712). 
 
 
Fig.  1: GALT 3D / Source: PDB (Protein Data Bank). GALT complexed with UDP-galactose. 
 
GALT is a homodimer. Each subunit is characterized by a nine-stranded antiparallel β-pleated 
sheet flanked on either side by two α-helices [1]. Three different ions are incorporated in each 
subunit to stabilize the enzyme, the dimerization, and the substrate binding. An iron ion is 
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located near the subunit interface it serves as a bridge between two β-strands and an α-helix. 
A further zinc ion is located near the active site of the substrate binding position of uridine 
and at the opposite side to the surface loops of the enzyme. The third metal ion, a potassium 
ion, stabilizes two phosphoryl groups of UDP after binding of the first substrate (UDP-
glucose) at the active site. Each loop of the dimer forms a component part to the active site of 
the opposite subunit.  
 
2.1.1.2 The GALT mutation Q188R 
 
A gene mutation causes the amino acid exchange from glutamine to arginine at position 188 
of the amino acid sequence of the enzyme (Q188R). The peptide site p188 is located at the 
active site. As a result for this exchange a mislinkage of the hydrogen bond from the upper 
phosphoryl groups (O2A/O1B) to the lower situated hydrogen bond types (O5´/O2B) 
rearrange (Fig. 2/Attm. p.68)[2]. This mislinkage is accompanied by a loose fitting of the 
second GALT substrate the cosubstrate gal-1-phosphate. The loose fitting causes the 
reduction of the enzymatic turnover rate by a factor greater than 1000. 
In addition, another destabilization effect is caused by the bulky arginine residue that exhibits 
a longer side chain in comparison to glutamine (Fig. 3/Attm. p.69)[2]. Moreover, the bulky 
arginine residue disturbs the dimeric close up of the subunits and negatively influences the 
substrate fitting to the surrounding hydrophobic pocket of the active site. 
 
2.1.1.3 Ping-Pong double displacement reaction of GALT 
 
GALT acts on two substrates in a ping-pong double displacement reaction (Fig. 4/Attm. p.70) 
[3]. Primarily, the first substrate UDP-glucose in composition with GALT binds to the active 
site that forms the intermediate complex GALT-UDP-glucose. It is subsequently cleaved to 
GALT-UMP. It remains attached to the enzyme in complex. Glucose-1-phosphate the first 
product that is released (“ping-reaction”). The second (co-)substrate added is galactose-1-
phosphate that forms the second intermediate complex GALT-UDP-galactose with GALT-
UMP. During the final step the second product UDP-Galactose is released by the enzyme 
(“pong-reaction”) and the GALT is ready to take part in another turnover cycle. 
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2.1.2 Galactose and the Leloir pathway 
 
Lactose, one of the major sources of galactose, is cleaved by lactase, a transmembrane 
enzyme that is located at the epithelial surface of the small intestine. More precisely, the 
enzyme is exposed on villi to the intestinal lumen. These villi carry active transporters as 
well, which are able to take up galactose in the way of a galactose-proton symport. The 
galactose subsequently enters the Leloir pathway (Fig. 5 see next p.), is phosphorylated by 
galactokinase and then serves as a cosubstrate of the GALT. GALT is the second enzyme in 
the Leloir pathway of galactose metabolism that converts galactose-1-phosphate to glucose-1-
phosphate which is metabolized in the glycolytic pathway. Alternatively, galactose-1-
phosphate may instead be activated to UDP-galactose, the cosubstrate involved in enzymatic 
galactosylation of glycoproteins and glycolipids. In this study we focused on the alternative 
pyrophosphorylase pathway correspondent to galactosylation of glycoproteins. UDP-
galactose and UDP-glucose are balanced by UDP-galactose-4-epimerase which is able to 
convert one activated sugar into the other, dependent on the substrate concentration. 
Deficiency of GALT should expectedly lead to an imbalance between UDP-galactose and 
UDP-glucose. The maladjustment might result in disglycosylation of glycoproteins and 
glycolipids. Deficiency of GALT results in a severely impaired galactose metabolism. The 
intracellular metabolite concentration of Gal-1-P was shown to accumulate more than five-
fold under galactose-stress and this has an effect on at least three enzymes of galactose 
metabolism: phosphoglucomutase, glucose-6-P-phosphatase and phosphorylase (three 
enzymes shown in Fig. 5 see next p.). 
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2.1.3 Dysglycosylation of secreted glycoproteins in classical galactosemia 
 
Reports on glycosylation abnormalities in galactosemic patients so far exclusively refer to 
secreted proteins, in particular to plasma glycoproteins such as transferrin and glycopeptide 
hormones such as follicle-stimulating hormone (FSH) [4-5]. Transferrin of galactosemic 
patients prior to dietary galactose restriction was shown to have large proportions of truncated 
glycans lacking terminal sialic acid and galactose residues in N-glycan antennae [6]. The 
distinct glycosylation abnormalities of transferrin prior to dietary galactose restriction were 
the consequence of the acute hepatotoxic status caused by exogenous galactose. These 
abnormalities should be distinguished from aberrant glycosylation which might be related to 
cell or tissue dysfunction responsible for the development of long-term complications. Rather, 
for such a harmful event abnormally glycosylated cellular glycoproteins come into 
consideration, since proper N- and O-glycosylation of glycoproteins is a precondition for 
proper sorting and trafficking of membrane glycoproteins, so that they can reach their correct 
destination and function [7]. Likewise, a defective synthesis of glycoproteins and 
galactolipids can have a strong impact on normal myelin formation [8]. Thus, in search for the 
role that aberrant glycosylation may play for the development of long-term complications in 
galactosemia the glycosylation of cellular glycoproteins should be studied. 
 
2.1.4 Clinical picture of classical galactosemia 
 
Newborn infants affected with severe GALT deficiency develop a potentially lethal 
hepatotoxic syndrome induced by dietary (exogenous) galactose, which usually resolves 
rapidly after institution of a galactose-restricted diet. In contrast to rapid recovery of liver 
disease, long term outcome in classical galactosemia is disappointing. Despite strict 
adherence to the galactose-restricted diet, a great percentage of patients develop long-term 
complications which may result from deleterious perturbations in cell biology caused by 
endogenously synthesized galactose. The long-term complications comprising cognitive 
impairment, speech defects, motor function disturbances and in most female patients 
hypergonadotropic hypogonadism are related to the CNS and ovary as target tissues. Their 
origin is prenatal. They worsen, if at all, only slightly with time [9-10]. The possible 
mechanisms underlying long-term complications comprise the individual or combined effects 
of excess galactose-1-phosphate, galactitol or other galactose metabolites, or defective 
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glycosylation of proteins and lipids leading to direct and  or indirect cell or tissue dysfunction 
[4]. A number of reports have demonstrated that GALT deficiency leads to aberrant protein 
glycosylation especially prior to dietary galactose restriction, but also in a diminished form 
under a galactose-restricted diet [5-6,11]. 
 
 
 
 
 
 
 
 
   http://learn.genetics.utah.edu 
Fig. 6: Affected organs in galactosemia: Primary effect on liver; secondary effect on kidney, brain and 
eyes. In the eye a characteristic grey deposit of galactitol could be recognized. 
 
2.1.5 Exosomes 
2.1.5.1 Characteristics of exosomes 
 
Exosomes are found in almost all body fluids that are exposed to epithelial surfaces: blood, 
urine, amniotic fluid, malignant ascites, bronchoalveolar lavage fluid, synovial fluid and 
mother’s milk [12]. They are able to communicate with the immune system via major 
histocompatibility complexes (MHC). Inside the lumen they carry mRNA and microRNA and 
can therefore influence protein expression if transferred to another cell. Typical exosomal 
marker proteins are: alix, TSG101, CD81 (tetraspanin), Hsp70, MUC1, GPI-anchored 
proteins like RhoA, G-proteins, receptor CD24, flotillin and caveolin. Exosomes exhibit a 
density of about 1.15-1.18 g/ml, consist of a double layer membrane and are highly enriched 
in sphingomyelin, cholesterol and the glycolipid GM3 [13]. Exosome-like vesicles were also 
found in the hemolymph of D. melanogaster and in supernatant of Schneider 2 cells [14] 
which characterizes them for an evolutionary conserved function. 
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2.1.5.2 Epithelial origin of exosomoes 
 
Human urine has been reported to contain exosomes [15], with sizes ranging between 30 and 
100nm. They originate from internal vesicles that are called intra luminal vesicles (ILV), 
accumulate in endosomal multi-vesicular bodies (MVB) and are then released after fusion of 
the MVBs with the cell membrane. The membrane of these nanovesicles exhibits a close 
relationship to the protein composition of the respective plasma membranes and hence these 
exovesicles can reveal insight into the proteome and glycome of the exosome forming cell 
[16-17]. In case of urinary exosomes, each renal epithelial cell facing the urinary tract 
contributes to the pool of exosomes. 
  
2.1.5.3 Exosomes are enriched in subpopulations of lipid rafts 
 
Transmembrane and membrane integrated proteins are often found in particular subdomains 
of the plasma membrane, called lipid rafts (see also below under 2.1.6.1). The 
transmembranous glycoprotein MUC1, for example, is sorted for trafficking via lipid raft 
platforms (Fig. 7 next p). Each of these lipid rafts is structurally stabilized by either caveolin-
1 or flotillins. The arrangement of these scaffolding proteins close to the cell surface induces 
an inward budding of the plasma membrane and the formation of vesicles. These vesicles are 
then transported to the early endosomes that mature to multivesicular bodies (MVBs) by a 
second inward budding. Inside the MVBs, proteins are sorted through ESCRTs (endosomal 
sorting complexes required for transport) and Vps-proteins (vacuolar protein sorting-proteins) 
into the membrane of the intra luminal vesicles (ILVs). Protein-ubiquitination therefore 
provides the targeting signal to these vesicles.  During the second inward budding the proteins 
regain the same orientation that they previously exhibited at the cell surface. Thus the 
extracellular part of the protein is exposed at the outside of the exosome. Finally, MVBs fuse 
with the membrane and release their content, now called exosomes, into the extracellular 
space (Fig. 7 next p). 
 
 19 
 
 
Fig. 7: Origin of exosomes. Glycoprotein trafficking from lipid raft to exosome. 
 
The surface of the exosomes thus represents a section of the plasma membrane, which is 
reflected in results of comparative proteomic analyzes [18]. 
 
2.1.6 Lipid rafts 
2.1.6.1 Lipid raft endocytosis 
 
Lipid rafts are enriched in sphingolipids, cholesterol and gangliosides their composition is 
distinct from the surrounding less ordered membrane. This lipid composition, in particular the 
high content of cholesterol, makes lipid rafts less soluble in the presence of neutral detergents, 
like Triton-X100 at 4°C, a feature, which is used during their preparation. The cholesterol 
reduces the lipid raft density a property that enables to fractionate them by gradient 
ultracentrifugation.  
Two types of lipid rafts can be distinguished: “planar lipid rafts” which are also referred to as 
“non-caveolar”, and a subset of rafts known as “caveolae”. Planar rafts are defined as non-
invaginated microdomains lacking specific morphological features. Caveolae, on the other 
hand, are tube-like invaginations of the plasma membrane characterized by specific 
scaffolding proteins, the caveolins. Functionally, lipid rafts can be regarded as sorting 
platforms for targeted transport of transmembrane and GPI-anchored proteins and hence their 
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protein compositions are highly fluctuating. Some proteins however are key components for 
membrane raft formation and function and can be found as constitutive components of rafts. 
One of the essential proteins serving scaffolding functions in caveolar raft formation is 
caveolin-1, a classical hairpin protein that plays a key role in caveolae-mediated endocytosis 
and transport.  
However, caveolin-1 is not the only protein involved in raft formation, as other proteins may 
be substituted for its scaffolding functions in caveolin-independent rafts. Reggie/flotillins, 
members of the SPFH-domain containing protein family (stomatin/prohibitin/flotillin/ 
HflK/C), are also an indispensable prerequisite for raft formation in non-caveolar or so-called 
reggie microdomains [19]. Reggie 1/flotillin-2 and reggie 2/flotillin-1 promote the co-
assembly of activated and specific GPI-anchored proteins in plasma membrane microdomains 
and allow similar to caveolin-1 a concerted interaction of signaling molecules (Src family 
kinases and the CAP-associated signaling complex in cooperation with the small GTPase 
TC10). Beyond their involvement in membrane raft formation and signaling, flotillins bind to 
actin and interact in this way with the cytoskeleton [20]. Flotillin is anchored in the lipid 
bilayer via N-terminal myristoyl and palmitoyl groups and associates with the membrane by 
binding two hydrophobic subdomains. On co-expression in caveolar rafts flotillins can 
interact with caveolin-1, and may serve as a functional substitute in caveolin-1-deficient cells, 
such as MCF-7 breast cancer cells. These cells are negative for caveolin-1 and lipid raft-
associated endocytosis is mediated by flotillin- and CDC42-dependent pathways. 
Summarized, reggie/flotillins show a distant relationship to other scaffolding proteins, in 
particular to stomatin, prohibitin, podocin and erlin. 
 
2.1.6.2 Glycoprotein trafficking via multivesicular bodies (MVBs) to exosomes 
 
The clustering of lipid rafts through oligomerization of raft components plays a role in the 
sorting of proteins and their trafficking to different cellular locations. Besides functioning in 
polarized sorting, raft formation might be involved in re-endocytosis and trafficking of 
membrane-bound glycoproteins to early endosomes, from where they can be transported to 
lysosomes or recycle back to the plasma membrane via the secretory pathway and undergo 
follow-up glycosylation (Fig. 8 Attm. p.71). A further possibility is that re-endocytosed 
membrane glycoproteins are sorted into exosomes for cellular export. An essential role of 
exosomes could be the homeostasis and adaptation of plasma membranous glycoprotein 
patterns. Hence, the exchange by de novo synthesized plasma membrane proteins and the 
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removal of immaturely glycosylated (undersialylated or unprocessed) species via lysosomal 
degradation or via exosomal export might be a way how cells regulate the exposure of a 
specifically glycosylated protein in apical membranes. One such protein, which is known to 
follow recycling and exosomal export pathways, is the type 1 transmembrane glycoprotein 
MUC1. This heavily O-glycosylated mucin was demonstrated to recycle several times 
through the trans-Golgi network and to gain in this way a maturation of sialylation. The re-
endocytosis and vesicular transport of the protein were shown to follow a clathrin-mediated 
pathway and later confirmed to be dependent on specific Tyr residues (Tyr20, Tyr60) in the 
highly conserved cytosolic domain of MUC1, which are necessary for binding to adaptor-
related protein complex 2 (AP2).  
The re-entry into the secretory pathway of MUC1 was revealed to be dependent on S-
palmitoylation of a CQC motif at the intersection of the cytosolic and transmembrane 
domains. The mucin can also be shed from the plasma membrane by action of specific 
sheddases or by dissociation of the heterodimeric complex formed by the extracellular tandem 
repeat domain and the membrane-bound component. Accordingly, exosome-depleted 
supernatant of cells transfected with a recombinant MUC1 probe was shown to contain a 
soluble form of the fusion protein that lacks the transmembrane and cytosolic domains 
(Razawi, H. and Hanisch, F.-G. unpublished results). 
 
2.1.7 The Tamm-Horsfall glycoprotein (THP) 
 
Tamm-Horsfall glycoprotein (THP, also called uromodulin) is highly (exclusively) N-
glycosylated, exposed at the epithelial surface, and can be shed after cleavage of the GPI 
anchor. Urothelial cells are the origin of the most abundant glycoprotein in human urine. THP 
is integrated into the plasma membrane via a GPI-anchor and hence represents an integral 
membrane protein [21]. However, it is shed in large quantities into urine, where its 
concentration can reach 0.5mg/dl. Both urinary constituents, exosomal membranes and THP, 
may generally serve as a suitable non-invasive starting material for bio (glyco) marker 
discovery. The THP is found at the cell membrane of the proximal tubulus of the nephron.  
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Fig. 9: Tamm-Horsfall protein, membrane integrated and cleaved. 
http://www.aist.go.jp/aist_e/latest_research/2006/20061110/20061110.html 
 
THP is a major contaminant that adheres to the surface of the exosomes as long filamentous 
protein polymers (Fig. 13 p.37 below). This oligomerisation is caused by disulfide linkage of 
cysteins inside the zona pellicuda domain of THP. THP polymers have been claimed to be 
removable under strong denaturing conditions [22], which was however not confirmed in our 
hands. 
 
2.1.8 N-glycan processing 
 
N-linked chains can be found in three different forms: The high-mannose-type, the hybrid-
type, and the complex-type. High-mannose-type glycoproteins are presented at the cell 
surface if N-glycoproteins pass the Golgi-network only once as in case of secretory proteins. 
In contrast, the complex-type glycans, as the name already implies, represent a structurally 
more diverse family of related structures, which differ with respect to the number of antennae, 
the lengths of antennary polylactosamines and the terminal epitopes. The hybrid-type 
represents an intermediate form, which is generated during processing of high-mannose-type 
glycans to the complex-type, a process involving the trimming by mannosidases and the 
addition of GlcNAc and Gal (Fig. 10 see next p.). If the synthesis of glycoproteins is 
interrupted because of an enzyme deficiency a lot of CDGs (congenital disorder of 
glycosylation) develop. The assembly of high-mannose-type glycans is restricted to the ER 
and CDG I defects are either restricted to this compartment. The oligosyltransferase (OST) 
divides the CDG I and CDG II diseases. Enzymatically disglycosylation that happens behind 
the oligosaccharide transfer of the OST were described as CDG II. The most part of 
secondary CDGs (CDG II) were allocated to the Golgi compartment where the modification 
of glycoproteins to complex-type occurs. 
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Fig. 10: The high-mannose-type glycoproteins are synthesized in the ER. The trimming to complex-
type proceeds inside the Golgi. Involved in the restructuring process are mannosidases, GlcNAc-
tranferases, Gal-transferase and Sialyltransferase. (C. Thiel & C. Körner 2011/Springer V.) 
 
2.1.9 Reabsorption of proteins in the kidney 
2.1.9.1 Megalin cubilin receptor complex 
 
“The kidney proximal tubule has a high capacity for the uptake of filtered proteins. Small 
proteins are mainly allowed to pass the glomerulus filtration barrier larger are filtered except 
in glomerulus dysfunction. The cut-off molecular weight for filtration of plasma proteins 
during normal conditions has generally been assumed to lie in the range of 60kD, which 
corresponds to the approximate molecular weight of serum albumin. However, the diversity 
of proteins filtered is large and includes also larger proteins such as transferrin (81kD). Thus, 
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the molecular apparatus for handling the reabsorption of these proteins must include the 
ability to recognize a large number of different proteins and at the same time provide for an 
efficient (re)uptake. The initial step in the reuptake of proteins involves receptor mediated 
endocytosis initiated by the binding of filtered ligands to receptors at the luminal surface, 
followed by the clustering of these receptors into clathrin coated pits at the base of the 
microvilli” [23]. 
“Furthermore, the accelerated tubular reabsorption of specific proteins is implicated in the 
progression of chronic renal disease characterized by proteinuria. The two large membrane-
associated proteins megalin and cubilin serve as endocytic receptors mediating the luminal 
uptake of a large number of proteins, including albumin, which are filtered both in the normal 
glomeruli and as a result of glomerular dysfunction” [23]. The accelerated tubular 
reabsorption probably is a consequence of a higher expression rate of both complex proteins.  
 
 
 
Fig. 11: Megalin cubilin reabsorption complex 
 
Megalin and cubilin was previously detected by a proteomic profiling study of exosomes by 
Pisitkun et al. but he could not link it to any disease dependent regulation [15]. Marzalo et al. 
[24] predicted the exosomal megalin involvement in renal diseases. Marzalo further describes 
the involvement of megalin in the central and peripheral nervous system and several of its 
ligands play a role in neuronal survival and regeneration [24].  
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2.2 The aims of the study 
 
This work refers to the first comprehensive study of a cellular N-glycoprotein 
dysglycosylation associated with classical galactosemia. The results demonstrate that findings 
from analyses of secretory glycoproteins cannot be regarded as representative for changes in 
the glycosylation of cellular membrane-bound proteins. Strikingly, the GALT-deficiency does 
not result in an under-galactosylation of complex-type N-linked chains, but instead in a 
dramatic shift from preponderant high-mannose-type N-glycosylation in control samples to 
(galactosylated) complex-type chains in GALT-deficient patients. 
The second part of this study recognizes renal failure in galactosemia and an increased 
amount of the megalin-cubilin complex that is strongly associated to proteinuria. The 
examination of urinary exosomal lipid rafts provides a new diagnostic method. Instead of 
kidney biopsy N-glycan analytic or the increased amount of some elected protein marker may 
serve for diagnoses of renal failure. 
  
 
3. Materials & Methods 
3.1 Materials 
3.1.1 Samples from GALT deficient patients  
 
Urine samples (approx. 500ml, collected in the morning) were obtained from healthy 
volunteers (adult individuals, n = 5) and from patients with classical galactosemia (12 adult 
individuals six female, six male; approved by the Ethical Commission of the University Clinic 
of Cologne on November 23rd, 2010) and kept frozen (-20°C) until use. The galactosemic 
patients carried the c.A1466G (p.Q188R) mutation homozygous and exhibited a very low 
residual GALT activity characteristic for classical galactosemia. All galactosemic patients 
were on a severely galactose-restricted diet. 
 
 
 
 26 
3.1.2 SDS-Polyacrylamide-gel electrophoresis buffers 
 
10 % SDS:        5g Na-dodecylsulfate in 50ml ddH2O 
Laemmli buffer (2x):       2 % SDS, 45 % glycerol, 0.01 % bromphenolblue, 
         100mM Tris-HCl (pH 6.8), 10 % ß-mercaptoethanol 
Electrophoresis buffer (10x):  0.25M Tris, 1.92M glycine, 1 % SDS, (pH 8.3) 
 
TGP (4x):    90.93g Tris / 0.5l / pH 8.8 adjustment with HCl (conc.)  
SGP (4x):    30.31g Tris / 0.5l / pH 6.8 adjustment with HCl (conc.) 
 
3.1.3 Transfer buffer for Wet blot 
 
Transfer buffer:   500ml 2x Towbin buffer (see below) 
     200ml methanol 
     5ml 10 % SDS solution 
     fill up to 1000 ml  
 
3.1.4 Other buffers 
 
TBS( T ):        50mM Tris-HCl pH 7.4, 
   0.15M NaCl, (0.05 % Tween 20) 
Towbin buffer (2x):    0.39M glycine, 0.048M Tris, 20 % methanol 
PBS:     PAA (Cölbe) 
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3.1.5 SDS-polyacrylamide gels 
 
 
 
 
 
 
 
 
 
Charts: Components (percent per volume) of SDS-polyacrylamide gels 
 
Protein samples were heated in sample buffer 5min. at 95°C. Afterwards these samples were 
subjected to SDS-PAGE. While the proteins pass through the stacking gel the amperage was 
set at 15mA. After entry into the resolving gel the amperage was increased to 20mA. 
 
3.1.6 Inhibitors 
 
Protease Inhibitor    Protease Inhibitor Cocktail (Sigma-Aldrich, Steinheim) 
     P8340 without EDTA (Sigma-Aldrich, Steinheim) 
     P2714 with EDTA (Sigma-Aldrich, Steinheim) 
cOmplete Protease  
Inhibitor Cocktail Tablets:  Roche Diagnostics (Mannheim) 
 
3.1.7 Staining solutions and dye 
 
10 % Ponceau-S-dye:      0.2 % Ponceau S (Merck, Darmstadt) in  
    3 % TCA / H2O (Fluka, Seelze) 
Coomassie Brilliant Blue       
Stain ( G250-solution ):     50 % methanol (Sigma-Aldrich, Steinheim), 
Resolving gels 5 % 20 % 
Water 5.7 2.5 
4 x TGP 2.5 2.5 
AA-solution 1.7 5.0 
SDS (10 %) 0.1 0.1 
APS (10 %) 0.05 0.05 
TEMED 0.005 0.005 
Stacking gel 4 % 
Water 6.1 
4 x SGP 2.5 
AA-solution 1.3 
SDS (10 %) 0.1 
APS (10 %) 0.05 
TEMED 0.01 
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 12 % acetic acid (Sigma-Aldrich, Steinheim),      
0.04 % Servablue G-250 (SERVA, Heidelberg) 
Destain-solution for 
Coomassie:      40 % methanol 
5 % acetic acid 
 
3.1.8 N-glycan detachment / methylation 
 
PNGase F:       New England Biolabs (NEB), Frankfurt  
Bicarbonate buffer (99.5 %, puriss.): KMF Laborchemie Handels GmbH (50mM)     
Iodomethane:    Sigma-Aldrich, Steinheim 
Acetic acid:    Sigma-Aldrich, Steinheim 
Chloroform (>99 %; anhydrous): Sigma-Aldrich, Steinheim 
Methanol (spec. grade):  Sigma-Aldrich, Steinheim  
 
3.2 Methods 
3.2.1 BioRad DC protein assay for high concentration 
 
A stock solution of 10mg/ml BSA was prepared to generate a standard curve (steps 0.2µg/µl; 
with eight dilutions 0-1.4µg/µl). The microplate “High-concentration assay” was chosen for 
protein determination. In brief, 5µl standards and samples, 25µl reagent A and 200µl reagent 
B were added to the microplate and incubated for 10-30min. The absorption (at 620nm) was 
measured by an ELISA Reader (TECAN). 
 
3.2.2 Preparation of urinary exovesicles 
 
Exosomes (and a minor proportion of other plasma membrane-derived vesicular material) 
were separated from 200ml urine by differential centrifugation at 4°C. The urine samples 
were initially filtered through Whatman filters and then centrifuged at 10.000 x g for 30min. 
This step was repeated to remove pelleted material, which was accidentally transferred during 
removal of the supernatant. In the next step the supernatant was ultracentrifuged at 114.000 x 
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g for 90min. The pelleted exovesicles were suspended in 200µl PBS and transferred into 
1.5ml tubes for a final ultracentrifugation at 135.000 x g for 60min. The exovesicles obtained 
by this centrifugation step were stored frozen at -20°C. 
 
3.2.3 Electron microscopy of exovesicular preparations 
 
A Formvar
©
 coated copper grid was placed on the exosome containing suspension for 30 
minutes to allow adhesion of exosomes. Then the grid was shifted to a drop of fixative for 15 
min. followed by washing 5 times for 1min in 0.1M PBS (after each washing step excessive 
liquid was removed with filter paper). Afterwards, the grid was applied to a solution 
containing 2 % uranylacetate for approximately 90s, washed 3 times on aqua bidest. for 1min. 
Finally, the excessive liquid was removed using filter paper. Thereafter, the grid dried at room 
temperature. 
 
3.2.4 Isolation of Tamm-Horsfall protein 
 
Exovesicle-depleted and neutralized urine was further processed for the isolation of Tamm-
Horsfall protein (THP) by filtration over a layer of 20g diatomaceous earth as described by 
Serafini-Cessi et al. [25]. Loading excessive protein in SDS gel electrophoresis the presence 
of only small amounts of contaminating proteins was revealed, which were however 
identified as unglycosylated (protein identification by LC-MS/MS (Fig. 32 Attm. p.86) of 
tryptic peptides as described in [26]. For analysis of N-linked glycans on THP, the protein 
was digested in-gel after gel electrophoresis and the eluted glycopeptides were treated with 
PNGaseF (see below). In-gel digestion with trypsin was performed under standard conditions 
as applied in proteomics workflows [26]. The (glyco-) peptides were eluted into two aliquots 
of 0.5ml acetonitril in water (50 %) with rotation for 2 x 2h at RT. The eluate was heated to 
90°C for 10min. to compensate residual protease activity and dried by vacuum rotation prior 
to addition of PNGaseF.  
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3.2.5 Release and purification of N-linked glycans 
 
N-linked glycans were released from the protein cores by digestion with PNGaseF. In detail, 
the samples (exovesicles or THP, each corresponding to 10-100µg protein, or tryptic 
glycopeptides from in-gel digestion) were taken up in 50µl 50mM ammonium bicarbonate 
buffer, pH 8.5, and briefly sonicated. PNGaseF (NEB, 250 U) was added and the reaction 
mixture was kept at 37°C for 16h. After drying by vacuum rotation the glycans were 
solubilized in 0.1 % aqueous trifluoroacetic acid (100µl) and separated from residual 
protein/peptides by passage over BondElutC18 (Variant/Agilent, 100mg, column) and 
washing off with 0.9 ml 0.1 % TCA. The procedure was followed by derivatisation and mass 
spectrometry (see below). The whole flow chart is schematically represented in Fig. 12 N-
glycosylation of exosomes (Attm. p.72) 
 
3.2.6 Derivatization of N-linked glycans 
 
The methylation procedure started after extensive drying of the sample by vacuum 
centrifugation followed by vacuum drying in a desiccator over P2O5/KOH for one hour. All 
procedures were performed in argon atmosphere. To the dry sample 100µl of alkaline (2.5 %, 
w/v, finely dispersed NaOH in dry DMSO) was added. The sample was briefly sonicated for 
1 – 2min. and incubated for 3 min. at RT with occasional shaking. Finally, an aliquot of 50µl 
methyl-iodide was pipetted to the frozen reaction mixture followed by incubation for further 
30-60min. at RT. Prior to the extraction step the reaction mixture can optionally be 
neutralized with 40µl of 1 M acetic acid. Extraction of methylated glycans was performed by 
stepwise addition of 0.3ml chloroform and 0.2ml bidest. water. After vigorous mixing and 
phase separation, the water layer was removed and repeatedly replaced by at least four further 
aliquots of 0.2ml. The chloroform phase was dried under nitrogen and the glycans were 
solubilized in methanol prior to application onto the MALDI target. 
 
3.2.7 MALDI-TOF-TOF mass spectrometry of methylated glycans 
 
Matrix-assisted laser desorption ionization (MALDI) mass spectrometry was performed on an 
UltrafleXtreme instrument (Bruker Daltonics, Bremen, Germany). The permethylated glycans 
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(approx. 500ng) resuspended in 20µl methanol were applied to the stainless steel target by 
mixing a 0.5µl aliquot of sample with 1.0µl of matrix (saturated solution of 2,5-dihydroxy 
benzoic acid in ACN / 0.1 % TFA, 1:2). Analyses were performed by positive ion detection in 
the reflectron mode. Ionization of crystallized analytes was induced with a pulsed Smart-
beam laser (accumulation of about 5.000 shots) and the ions were accelerated in a field of 
20kV and reflected at 23kV.    
 
3.3 Differential proteomics by application of the i-TRAQ-technology 
3.3.1 Preparation of lipid rafts out of urinary exovesicles 
 
Exosomal lipid rafts were separated from 200ml urine by differential centrifugation and 
incubation with Triton X-100 at 4°C. The urine samples were initially filtered through 
Whatman filters and then centrifuged at 10.000 x g for 30min. The centrifugation step was 
repeated once. Eight centrifugation bottles (V = 26ml, Beckmann Ti 60 rotor) were layered 
with 2.6ml of 10 % Triton X-100 and filled up to a volume of 26ml to a final concentration of 
1 % Triton X-100. The samples were incubated for 30 min. on a rotator at 4°C. The next step 
was an ultracentrifugation at 114.000 x g for 90min. The pelleted exosomal vesicles were 
suspended in 200µl cold PBS (4°C) combined and transferred into 1.5ml tubes for a final 
ultracentrifugation at 135.000 x g for 60min. (4°C). The pelleted exosomal lipid rafts obtained 
by this centrifugation step were stored frozen at -20°C after removal of nearly all aqueous 
supernatant with a pipette. 
 
3.3.2 Protein quantitation in the context of i-TRAQ experiments 
 
To the stored pelleted samples 100µl cold PBS was added the samples were sonicated on ice 
with three strokes at lowest energy level. The amount of protein was quantified using the 
standard Lowry DC assay. An aliquot equivalent to 50µg protein was chloroform/methanol 
precipitated, the pellet air dried for 10 minutes and further processed by filter-aided sample 
preparation (FASP). 
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3.3.3 Chloroform / methanol-precipitation 
 
Proteins were precipitated by methanol/chloroform precipitation as follows:  
One volume of sample was mixed with four volumes methanol, one volume of chloroform 
and 3 volumes of ddH2O. After centrifugation at 16.100 g for 10 min. the aqueous phase was 
removed without disturbing the protein-containing interphase. Four volumes of methanol 
were added, the sample was mixed thoroughly and again centrifuged at 16.100 g for 10 min.  
The supernatant was removed and the pellet air dried for 10min. 
 
3.3.4 Filter assisted sample preparation (FASP) 
 
A volume of 20µl 125 mM Tris HCl pH 6.8, 4 % SDS, 20 % glycerol was added to the air 
dried sample. To lyse proteins, 2µl 1M dithiothreitol were added, the samples were heated to 
96°C for 10min, cooled down to ambient temperature and sonicated 3 x 10sec. After 
centrifugation at 14.000rcf for 5min. at 20°C the supernatants were transferred to 
Amicon Ultra  centrifugal filter units (0.5ml, 10K). Filter assisted sample preparation 
(FASP) with sequential Lys C (40ng/µl) and trypsin (10ng/µl) digestion was performed 
according to Wisniewski et al. [27] with minor modifications: Briefly, apart from the  initial 
lysis buffer, 0.1M TrisHCl was replaced by 0.1M triethylammonium bicarbonate (TEABC) 
pH 8.5  in all buffers used. After digestion the samples were centrifuged and filtrates were 
collected. 60µl 10 % acetonitril in water were added to the filter, mixed with the residual 
sample and the units were centrifuged once more. Combined filtrates were applied to C18 
Pepclean  spin columns (Thermo) activated with 80 % acetonitril and equilibrated to 0.1M 
TEABC. The absorbed sample was washed two times with 100µl 0.1M TEABC and desalted 
peptides were eluted with 20µl 80 % acetonitril in 0.1M TEABC. 
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3.3.5 iTRAQ labeling 
 
Sample volumes were reduced to approximately 10µl in a centrifugal evaporator, 15µl of 1M 
TEABC were added and volumes were adjusted to 30µl with bidest. water. iTRAQ reagents 
(AB Sciex) were dissolved in 70µl ethanol and mixed with the corresponding samples 
immediately. After 2h incubation at ambient temperature in the dark, labeled samples were 
combined and desalted using a PepClean  spin column as described above. However, 0.1M 
TEABC was replaced by 0.1 % formic acid in all steps. After salt removal, samples were 
dried in a centrifugal evaporator and resuspended in 50µl of 40 % acetonitril in 0.1 % formic 
acid. SCX tips were prepared with 1mg BioBasic 5µm SCX resin (Thermo) packed into a 
200µl C8 StageTip. Samples were loaded onto a SCX tip equilibrated in 40 % acetonitril in 
0.1 % formic acid. After washing with 2 x 20µl equilibration buffer, peptides were eluted with 
20µl 0.5M sodium chloride, 40 % acetonitril in 0.1 % formic acid. Acetonitril was removed 
by brief vacuum centrifugation and samples volumes were adjusted to 20µl with 0.1 % TFA. 
 
3.3.6 MALDI Spotting 
 
Peptides were separated by reversed phase HPLC on an Eksigent nanoLC 1D plus system 
(Axel Semrau GmbH, Sprockhövel, Germany) using a vented column setup comprising a 0.1-
mm-by-20-mm trapping column and a 0.075-by-200-mm analytical column, both packed with 
ReproSil-Pur C18-AQ, 5µm (Dr. Maisch, Ammerbuch, Germany) and operated at 40°C. 18µl 
sample were aspirated into the sample loop and a total of 30µl was loaded onto the trap 
column using a flow rate of 6µl/min. Loading pump buffer was 0.1 % TFA. Peptides were 
eluted with a gradient of 5 % to 35 % acetonitril  in 0.1 % TFA over 70min. and a column 
flow rate of 300nl/min. 0.7mg/ml alpha-Cyano-4-hydroxycinnamic acid (HCCA) in 95 % 
acetonitril in 0.1 % TFA, 1mM ammonium phosphate were fed in using a syringe pump 
operated at 150µl/h and a post column T-union. 384 fractions (10 seconds) were deposited 
onto a MTB AnchorChip 384-800   MALDI target (Bruker Daltonics, Bremen, Germany) 
using a Probot  (Dionex, Idstein, Germany)  fraction collector. 
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3.3.7 LC-MALDI MS/MS analysis 
 
MALDI MS and MS/MS analysis were carried out on an Ultraflextreme   MALDI-
TOF/TOF mass spectrometer (Bruker Daltonics) operated with a laser repetition rate of 1 
GHz. The process of data acquisition was controlled by Flexcontrol 3.0 and WarpLC. MALDI 
MS spectra were acquired over a mass range from 700Da – 4.000Da. Spectra were calibrated 
externally using the Peptide Calibration Standard II (all Bruker Daltonics) on the designated 
target calibration spots. The laser was used with a fixed energy setting and 3.000 shots / 
spectrum were collected from random raster points. Precursor ions with a signal to noise ratio 
equal or better than 10, were chosen for MS/MS analysis. Identical peaks in adjacent spots 
were measured only once, generally from the spot with maximum peak intensity. The 
software was programmed possibly not to take more than 20 MS/MS spectra from one spot. 
However, this is a “soft” value that was exceeded if no alternative positions were available. 
Polymer signals and peaks appearing in more than 40 % of all spots were filtered out. MS/MS 
spectra (3.500 shots) were acquired with the instrument calibration and iTRAQ reporter ions 
as well as peptide immonium ions were used for internal recalibration. 
 
3.3.8 Database Searches 
 
MASCOT 2.2 (Matrix Science Ltd, London, UK) was used to search a composite decoy 
database which was built from the UniProt database (August 10th 2010, 519348 sequences; 
183273162 residues). The composite database was generated with the Perl script 
makeDecoyDB (Bruker Daltonics, Bremen, Germany) which added a shuffled sequence and a 
tagged accession number for each entry. The tagged accessions were used for the calculation 
of false positive rates in Proteinscape 2.1. Searches were submitted via Proteinscape (Bruker 
Daltonics, Bremen, Germany) and the following parameter settings: enzyme “trypsin” with 1 
missed cleavage; species “human”; fixed modifications “carbamidomethyl”, “iTRAQ4plex 
(K)”, “iTRAQ4plex (N-term)”; optional modifications “Methionine oxidation”, “iTRAQ4plex 
(Y)”. The mass tolerance was set to 20ppm Da for MS and 0.8Da for MS/MS spectra. Protein 
lists were compiled in Proteinscape. Peptide hits were accepted when the ion score exceeded a 
value of 20. Protein hits required at least one peptide hit exceeding a peptide score of 30. In 
addition, the hits to decoy entries were used to calculate a minimal protein score which is 
required to keep the false positive rate below 2 % on the protein level [28]. 
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3.4 Identification of exosomal vesicles by detection of marker proteins in 
density gradient fractions 
3.4.1 Preparative gradient centrifugation of urinary vesicles 
 
Exosomes (and a minor proportion of other plasma membrane-derived vesicular material) 
were separated from 200ml urine by differential centrifugation at 4°C. The urine samples 
were initially filtered through Whatman filters and then centrifuged at 10.000 x g for 30min. 
This step was repeated to remove pelleted material, which could be accidentally transferred 
during removal of the supernatant. In the next step the supernatant was ultracentrifuged at 
114.000 x g for 90min. The pelleted exovesicles were suspended in a total volume of 400µl in 
PBS and layered on top of a sucrose gradient. The gradient 5-45 % sucrose was generated 
using a gradient mixer. The gradient was prepared in 8.5ml tubes (SW41) for a final 
ultracentrifugation at 114.000 x g for 4h. The exovesicles were collected in six fractions 
(1.4ml) by the use of an electric pump. The fractions were diluted with PBS and finally 
centrifuged in 8.5ml tubes (SW41) 200.0000 x g for 1.5h. The pellet was suspended in 
Laemmli buffer and applied on SDS-PAGE. 
 
3.4.2 Detection of exosomal marker proteins by Western blot 
 
Exosomal lipid rafts were prepared as described above by gradient centrifugation at 114.000 g 
and a final washing step. SDS-buffer was added to dissolve the proteins from rafts and the 
sample was heated to 70°C for 15min. The samples were centrifuged at 13.000rpm at 4°C for 
5min. Supernatant was stored at -20°C or subsequently loaded onto SDS-PAGE (4 % stacking 
gel, 5–20 % gradient running gel) in a Mini Protean 3 cell (BioRad, Munich, Germany). The 
gel was equilibrated in transfer buffer (20M glycine, 24mM Trizma-base, 20 % methanol) 
before it was wet-blotted (BioRad) onto a nitrocellulose membrane (Schleicher and Schuell, 
Einbeck, Germany) at 90mA overnight. Thereafter, the membrane was blocked in TBS 
containing 5 % non-fat dried milk and 0.1 % Tween 20 for 1h at room temperature (RT) 
before incubation with the primary antibody (overnight at 4°C). Immunocomplexes were 
labeled with HRP-conjugated secondary antibody and detected using a Lumilight Kit (Roche). 
Between each incubation step, the membrane was washed three times with TBS (20mM Tris-
HCl, 137mM NaCl, pH 7.6). Exosomes were isolated as described in section 3.2.2 
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(Preparation of urinary exosovesicles). For Western blotting, exosomes were heated for 
15min. at 70°C in SDS-buffer, following the same procedure described above. 
 
3.4.3 Antibodies 
 
Primary antibodies: anti-MUC1, C595 IgG (mouse monoclonal IgG), 1.1mg/mL, kindly 
provided by Dr. M. Price, Cancer Research Laboratory, University of Nottingham, 
Nottinghamshire, UK; anti-flotillin-2, sc-28320, Santa Cruz Biotechnology (mouse 
monoclonal IgG); anti-Hsp70, 3C5 hybridoma, (mouse monoclonal IgG), kindly provided by 
workgroup Prof. Höning, Cologne; anti-β-actin, A5316, Sigma (mouse monoclonal IgG); 
anti-α-tubulin, T5168, Sigma (mouse monoclonal); anti-Gα subunit, sc-262, Santa Cruz 
Biotechnology (rabbit polyclonal IgG); anti-glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), MAB374, Chemicon (mouse monoclonal IgG); anti-alix, sc-166952, Santa Cruz 
Biotechnology (mouse monoclonal IgG), anti-hsp27, sc-13132, Santa Cruz Biotechnology 
(mouse monoclonal IgG); anti-CD81, sc-7637 Santa Cruz Biotechnology (mouse monoclonal 
IgG); anti-cav-1, sc-894, Santa Cruz Biotechnology (rabbit polyclonal IgG); anti-EGFR, sc-
1005, Santa Cruz Biotechnology (rabbit polyclonal IgG). Secondary antibodies: Rabbit anti-
mouse IgG, HRP (P0260/Dako, Hamburg, Germany); swine anti-rabbit IgG, HRP 
(P0399/Dako). 
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4. Results 
4.1. Vesicle classification by electron microscopy and exosomal marker 
proteins  
 
Besides exosomes the exovesicle fraction of human urine possibly contains other types of 
vesicular material derived from epithelial plasma membranes of the urothelium,  apoptotic 
blebs (AB), microparticles (MPs) or microvesicles (MVs)[12]. Exosomes comprise vesicles 
with a size of 40-100nm while microvesicles are generally larger, ranging between 100 and 
>1000nm. Differing from exosomes the microvesicles bud directly from the plasma 
membrane. MVs were described as vesicles secreted as response to biological stimuli which 
could partially overlap in size with exosomes and MPs [12]. Furthermore MPs with a size of 
100-1000nm are larger than exosomes.  
In this study electron microscopy of crude exovesicle fractions from human urine revealed 
exosome-like, cup-shaped vesicles in the expected size range (Fig. 13).  
 
 
 
Fig. 13: Electron micrograph of exovesicular preparations from human urine demonstrating the 
preponderant presence of exosomes (upper and middle panel) and the binding of exosomes to 
polymerized THP (lower panel). 
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Western blot analyses of marker proteins, like alix, exclusively belong to the endocytic 
pathway via MVBs (Fig. 14 Attm. p.73) and confirmed the presence of exosomes.  
At this point reference to the differential proteomics experiments is made (see Tab. 4a Attm. 
p.90) which revealed a series of further marker proteins exclusively found in the exosomal 
pathway. The detection of genuine raft proteins, MVB proteins (e.g. Tsg101, or vacuolar 
sorting proteins), lysosomal proteins and many exosome associated proteins, leads to the 
conclusion that in fact mostly exosomal vesicles were enriched from the urine samples.  
In previous studies exosomes were often found to adhere to filamentous structures [22], which 
arise from THP polymerization via disulfide linkage from inside the zona pellucida domains. 
This phenomenon likely explains the contamination of exovesicular proteins by THP (see Fig. 
13 p.37 and Fig. 15 Attm. p.74). Filtered exovesicular fractions (cut-off at 100nm), which 
were depleted of MPs, revealed similarly high THP contaminations, but drastically reduced 
yields and a membrane fragmentation was observed (Fig. 16 Attm. S.75). Western blots of 
fractions from a density gradient centrifugation demonstrated that the exovesicles from 
human urine preferentially co-migrate with high-density fractions characterizing the buoyant 
density of exosomes and were positive for a variety of exosome characteristic marker proteins 
(Fig. 14 Attm. p. 73). Irrespective of these findings, this report refers only to urinary 
exovesicles (without further specification) as an easily accessible source of material from 
patient-derived epithelial membranes. 
 
4.2 N-glycosylation of exosomes 
4.2.1 Differential N-glycomics of the urinary exovesicles from galactosemia 
patients and healthy controls 
 
Exovesicles prepared from 100ml of human urine were measured to contain an average of 
about 200µg protein (with individual fluctuations between 60 and 600µg). Enzymatically 
cleaved N-linked glycans were estimated by reference to an internal standard (lacto-N-
fucopentaose I) to make up 0.5-5µg per 100µg of protein. The permethylated glycans were 
analysed by MALDI-TOF and TOF/TOF mass spectrometry to permit insight into the patterns 
of N-linked chains based on molecular masses and the calculated monosaccharide 
compositions in terms of Fuc (F), Hex (H), HexNAc (N), or NeuAc (S) and based on 
fragment masses (sequence information from protonated B-type ions according to the 
nomenclature of Domon and Costello [29]. In figure 17 and 18 two representative survey 
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spectra of methylated N-glycans from a galactosemic patient and from a healthy control 
individual are shown:  
 
Fig. 17: MALDI mass spectrum exosome derived N-glycans of a galactosemic patient  
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Fig. 18: MALDI mass spectrum; exosome derived N-glycans of a healthy persons  
Fig. 17/18: Representative MALDI mass spectra of permethylated N-glycans from urinary exovesicles 
of GALT-deficient patients and healthy control subjects 
Mass signals corresponding to a calculated composition of H3+nN2, with n = 0-6 represent high-
mannose-type glycans M3 to M9; mass signals corresponding to a calculated composition of HnNn 
(with n>3) represent undergalactosylated complex-type species, and mass signals corresponding to a 
composition of H3+nN2+m, with n = 1-4, m = 2-4 represent complex-type N-glycans. Major signals 
correspond to the sodium adducts M+Na that have lost NaOCH3. STD refers to the internal standard 
LNFPI. 
 
4.2.2 High-mannose and complex-type N-glycans 
 
The mass spectrometry patterns of N-linked glycans on urinary exovesicles were 
characterized by the presence of two classes of chains, the high-mannose-type glycans 
comprizing mostly M4 to M9, and the complex-type glycans, which were predominantly of 
the bi-antennary subtype A2 without core-fucosylation (Fig. 19 Attm. p.76). Other subtypes 
were undergalactosylated complex-type species with GlcNAc terminating antennae and 
glycans of higher antennarity. Qualitatively, the patterns revealed for GALT-deficient patients 
and the respective healthy controls overlapped to a large extent. On quantitative evaluation of 
the data, which were based on the summarized signal intensities for high-mannose-type 
glycans (H3+nN2, with n = 0-6) and complex-type glycans (H3+nN2+m, with n = 1-4, m = 2-4) 
exovesicles from healthy controls showed patterns of N-glycans that were dominated by high-
mannose-type vs. complex-type glycans (ratio about 3:1) (Table 1 see below). 
 
 
 
 
 
 
 
 
 
 
Table 1 
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Relative amounts of High-mannose- and Complex-type N-glycans in exovesicular membranes 
from galactosemic patients and healthy control subjects 
 
Galactosemic patient 1 2 3 4 5 6
 N-linked Glycans m/z % % % % % %
 High mannose 1322 4,43 2,73 9,52 6,64 6,99 4,78
1526 16,93 9,77 19,58 12,50 16,41 12,97
1730 16,13 27,73 20,37 10,55 29,18 11,60
1934 10,08 7,81 7,14 4,69 6,08 5,46
2138 4,03 1,17 3,17 2,34 2,13 4,44
Σ 51,6 49,21 59,78 36,72 60,79 39,25
 Complex type 2378 8,06 17,19 12,17 12,50 13,98 14,33
2552 4,44 3,52 3,44 3,13 1,82 11,60
2739 29,4 17,58 18,52 39,84 17,93 22,53
2913 5,64 3,52 2,65 5,08 1,82 8,53
3188 0,4 6,64 2,65 1,56 3,34 2,39
3724 0,4 2,34 0,79 1,17 0,30 1,37
Σ 48,34 50,79 40,22 63,28 39,19 60,75  
 
 
Galactosemic patient 7 8 9 10 11 12
 N-linked Glycans m/z % % % % % %
 High mannose 1322 7,73 10 9,04 8,30 10,26 8,06
1526 14,49 8,75 18,81 12,91 34,38 22,82
1730 12,08 17,5 9,76 8,75 8,92 18,79
1934 4,83 7,5 2,53 2,50 2,09 6,71
2138 3,38 2,5 2,71 2,92 3,80 2,68
Σ 42,51 46,25 42,85 35,38 59,45 59,06
 Complex type 2378 13,53 15 11,21 13,33 6,93 12,08
2552 10,63 10 3,98 2,91 2,85 4,03
2739 13,53 16,25 36,89 42,08 24,98 24,83
2913 12,56 6,25 3,62 5,00 2,94 0,00
3188 4,35 3,75 0,54 0,41 1,71 0,00
3724 2,90 2,5 0,90 0,83 1,34 0,00
Σ 57,50 53,75 57,14 64,56 40,75 40,94  
 
Healthy control 1 2 3 4 5
 N-linked Glycans m/z % % % % %
 High mannose 1322 3,59 6,51 5,04 1,83 4,73
1526 34,08 29,99 30,56 7,93 23,67
1730 22,87 23,20 22,85 62,80 23,27
1934 10,31 11,32 12,46 7,93 14,60
2138 4,93 4,81 5,34 0,61 7,30
Σ 75,78 75,83 76,25 81,10 73,57
 Complex type 2378 6,28 3,96 5,64 3,05 7,10
2552 2,69 6,51 4,75 4,88 4,34
2739 11,21 5,37 6,23 1,83 6,70
2913 1,79 6,51 4,75 3,66 5,52
3188 1,79 0,71 1,48 3,05 1,58
3724 0,45 1,13 0,89 2,44 1,18
Σ 24,21 24,19 23,74 18,91 26,42  
 
% = ratio of single peak intensities to total listed peak intensities. m/z-values correspond to the 
molecular ions M+ Na (-54). Only major signals were considered in the quantitative evaluation. 
 
Contrary to this, GALT-deficient patients expressed dramatically increased proportions of 
complex-type chains on exovesicular glycoproteins with a ratio of about 1:1 (Fig. 20).  
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Fig. 20: Column diagram showing relative amounts of high-mannose-type vs. complex-type.  
N-glycans on urinary exovesicular membranes from GALT-deficient patients and healthy controls.  
Left panel: column diagram of relative amounts of high-mannose-type and complex-type N-glycans 
with indicated standard deviations; right panel: box-and-whisker plot of the ratio of relative amounts 
of complex-type vs. high-mannose-type N-glycans. The box indicates the lower and upper quartiles 
and the central lines are the medians. The points at the ends of the whiskers show the 2.5% and 97.5% 
values (centiles). Healthy controls, n = 5; GALT-deficient patients, n = 12. 
 
The shift of relative amounts of complex-type vs. high-mannose-type glycans from 0.32 to 
1.08 (factor: 3.4) can be regarded as even underestimated due to the presence of THP in 
exovesicular fractions, which is shown in this study to be glycosylated preponderantly with 
high-mannose-type glycans in patients and healthy controls. The presence of THP in 
exovesicular preparations however did not strongly influence the ratios of complex- vs. high-
mannose-type glycans in samples with high or low THP content (Suppl. Tab. 1 p.88). The 
variations of ratios (complex-type vs. high-mannose-type glycans) measured for independent 
urine samples from individual healthy control subjects were only small (Suppl. Tab. 2 p.89).  
 
4.2.3 Bi-antennary complex-type glycan, the most abundant structure 
 
The most dominant complex-type glycans from exovesicular membranes of GALT-deficient 
patients were of bi-antennary structure and lacked core fucosylation (Fig. 17 p.39). Only trace 
amounts of structures with higher antennary branching were found. There was a considerable 
fraction of N-glycans with complex-type structure that had a monosaccharide composition of 
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HnNn (with n = 4 or 5) and fluctuated from 15 % to 30 % between individual samples in that 
fraction. These compositions indicate the presence of under-galactosylated species, which 
were however found in both sample series from GALT-deficient patients and healthy controls 
without obvious quantitative correlation with one of the sample groups. The structures of the 
major components in the fractions of N-linked glycans were corroborated by MALDI-TOF-
TOF MS2 analysis (representative examples shown in Fig. 21/22 (see below). The M+Na (-
54) species (loss of sodium methylate) fragment under laser-induced dissociation conditions 
similar to the protonated MH species, which yield preferentially B-type proton adduct ions 
from the non-reducing terminal of the glycans in all MS2 spectra. Fragmentation by post-
source decay is preferred at C1-O bonds of HexNAc moieties explaining the restricted set of 
B ions. 
 
 
 
Fig. 21: MS2 spectrum of the monosialylated bi-antennary complex-type N-glycan registered at the 
precursor ion mass (M+Na) at m/z 2377 
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Fig. 22: MS2 spectrum of the high-mannose-type N-glycan M6 registered at m/z 1730 
 
4.3 The GPI-anchored transmembrane Tamm-Horsfall Protein 
4.3.1 N-Glycosylation of urinary Tamm-Horsfall Protein (THP) 
 
The analysis of urinary THP, the major N-glycoprotein shed exclusively by epithelial cells of 
the thick ascending limb of Henle's loop (TALH) and of the distal convoluted tubule lumen 
(UniProt), offers the chance to get independent evidence on disease-related alterations in 
cellular N-glycosylation of proteins. However, there is also a necessity to characterize the N-
glycoprofiles of this protein, since it generally forms a major protein component of 
exovesicular preparations from urine due to its adherence to the outer surface of exovesicles 
as a long filamentous protein polymer (Fig. 13 p.37). These THP polymers have been claimed 
to be removable under strong denaturing conditions [22], which was however not confirmed 
in our hands. We used DTT, 200mg/ml at 37°C, 10min. to remove THP from complete 
exosomes and exosomal lipid rafts (Fig. 23 Attm. p.77). We compared fresh isolated 
exosomal samples of a healthy person with stored samples (-20°C) of a galactosemia patient. 
Both samples exhibit high amounts of THP in the untreated samples (shown in line 1 and 4). 
The DTT treated samples (lines 2 and 5) show a decrease of THP, which was however not 
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removed completely. Also after addition of TritonX-100, a detergent often used in the 
preparation of exosomal lipid rafts (lines 3 and 6), the samples still exhibit strong THP 
contamination after DTT treatment. The results suggest DTT does not completely remove 
THP, it merely reduces the amount slightly. The THP contamination is also independent of 
the preparation route starting from fresh or thawed urine. Both samples, either from healthy 
controls or from galactosemia patients, contained THP and it adhered strongly to the 
exosomes.  
 
4.3.2 Validation of predominant high-mannose-type N-glycosylation of exosomal 
lipid raft associated THP 
 
Coomassie-stained SDS-gels of exovesicular proteins display THP as a major contaminant, 
which could have impact on the measured glycoprofiles. For this reason we analyzed the N-
glycans on THP separated from whole exosomal lipid raft samples, of patients as well as 
controls, by in-gel trypsin digestion of the electrophoretically separated protein, followed by 
elution of the glycopeptides and PNGaseF catalyzed liberation of the N-linked glycans. In 
contrast to the total exovesicular membranes, THP was characterized by the predominant 
expression of high-mannose-type N-glycans (Fig. 24/25 Attm. p.78/79). Throughout the M6 
isoform was most dominant, which is in agreement with earlier studies on THP glycosylation 
[30]. The N-glycosylation pattern of THP showed no major individual fluctuations and was 
unchanged in samples from patient urine (Table 2 see below). These data strikingly support 
the validity of the above described N-glycosylation shifts on exovesicular membranes, since 
the contaminating THP can only contribute to the pool of high-mannose-type chains in 
samples, but cannot be responsible for the dramatic increases of complex-type chains (Table 1 
p. 41). 
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Table 2  
 
Relative Amounts of High-Mannose- and Complex-Type N-Glycans on Urinary THP from 
Galactosemic Patients and Healthy Control Subjects 
Galactosemic patient 1 2 3 4 5
 N-linked Glycans m/z % % % % %
 High mannose type 1322 8,6 6,0 15,9 7,5 7,7
1526 20,3 16,8 32,7 22,6 27,3
1730 57,5 68,8 34,1 54,9 56,9
1934 7,4 6,4 12,0 6,0 7,7
2138 6,2 0,0 5,3 0,9 0,0
Σ 100,0 98,0 100,0 91,9 99,6
 Complex type 2378 0,0 2,0 0,0 3,1 0,4
2552 0,0 0,0 0,0 5,0 0,0
2739 0,0 0,0 0,0 0,0 0,0
2913 0,0 0,0 0,0 0,0 0,0
3188 0,0 0,0 0,0 0,0 0,0
3724 0,0 0,0 0,0 0,0 0,0
Σ 0,0 2,0 0,0 8,1 0,4  
 
Healthy control 1 2
 N-linked Glycans m/z % %
 High mannose 1322 5,78 7,47
1526 14,05 16,95
1730 60,33 62,64
1934 7,44 11,49
2138 0,00 0,86
Σ 87,60 99,41
 Complex type 2378 2,73 0,57
2552 0,00 0
2739 0,91 0
2913 0,00 0
3188 0,00 0
3724 0,00 0
Σ 3,64 0,57  
  
% refers to the ratio of single peak intensities to sum of annotated peak intensities. m/z-values 
correspond to the molecular ions measured as M-54 (loss of sodium methylate). Only major signals 
were considered in the quantitative evaluation. 
    
4.4 Differential proteomics of exosomal membranes 
4.4.1. Isobaric tags for relative and absolute quantitation 
 
Two samples of exosomal lipid rafts from galactosemic patients and two corresponding 
controls were analyzed by an in vitro technique (iTRAQ). The four samples were previously 
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applied on SDS-PAGE (Fig. 26 Attm. p.80). Remarkable was that the protein pattern of the 
two galactosemia samples were similar among each other. In the same way the samples of the 
healthy persons, but between healthy and galactosemia they were markedly different. 
iTRAQ is based on the differential labeling of proteome-derived peptides isobaric mass tags. 
These mass tags generate reporter ion fragments in MS2, which are used for the quantification 
of the protein-derived peptides. We used an offline nano-LC-MALDI-TOF-TOF setting 
without intermediate prefractionation, since the proteome under analysis was of low to 
medium complexity. Statistical evaluation of the four data sets revealed high validity for both 
the protein identification (Mascot scores) as well as the regulation factors (coefficient of 
variation). More than 200 proteins were identified, among which only a minor fraction was 
assigned to be genuine exosomal proteins. A major portion of the proteins was either of serum 
origin (serum glycoproteins) or had a functional relationship with the extracellular matrix. 
Many identified genuine exosome (Tab. 4a p.90) as well as exosome associated (Tab. 4b 
p.91) proteins were detected in accordance with published data of urinary exosomes 
proteomics [15-16,31-32]. The proteins listed under MVB and lysosomal proteins (Tab. 4f 
p.95) are characteristically found in exosomes, even though these proteins were divided into 
subgroups to give a better overview. 
Genuine exosomal lipid raft proteins, MVB and lysosome-associated proteins are slightly less 
than two-fold increased and are only rarely N-glycosylated. But alix, for example, was found 
in slightly reduced amount (Tab. 4e p.93) and we were able to validate this by Western blot 
(Fig. 27 Attm. p.81). Adversely, CD81 seems to be slightly more abundant in galactosemia 
(Fig. 27 Attm. p.81) and MUC1 expression was shown to be constant in several Western blots 
(Fig. 31 Attm. p.85). In contrast to the not markedly varying amounts of genuine exosomal 
proteins, there are many N-glycosylated proteins found in strongly increased amounts in 
patient-derived exosomes. All markedly increased proteins that are listed in Tab. 4b p.91 
under the topic “Exosome-(assoc.)” carry N-glycans and most of them exhibit a function as 
membrane-integrated cell surface located protein (UniProt). 
 
4.4.2 Proteins found increased 
4.4.2.1 Serum proteins 
 
As shown in Tab. 4c p.92, under subcategory “disease associated proteins”, the most 
abundant proteins are amylase, LRG1 (leucine-rich alpha-2-glycoprotein), fetuin, 
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prostaglandin, perlecan, alpha-1-microglobulin protein (AMBP) and serum albumin. All these 
proteins were connected in UniProt to TBMN/IgAN, proteinuria and renal damage. Even in 
healthy persons amylase could be measured in the blood serum and in low amounts in urine, 
yet it is only found more abundant in urine of renal failure. Only little information was found 
about LRG1 in UniProt. Li et al. detected the glycoprotein in urine as well [33] and suggests 
the protein as a biomarker candidate for detecting NSCLC (non-small cell lung cancer). At 
this research stage this assumption is not justified, because any cancer-associated changes are 
likely to be superimposed by renal failure-associated changes. Heo et al. noticed elevated 
glycoprotein levels in blood sera [34] (in human lung adenocarcinoma). Despite the devious 
marker function for cancer it seems to by a typical serum protein that could be found in high 
levels in renal failure. More abundant fetuin (alpha-2-HS-glycoprotein) is proposed to be a 
biomarker in urinary exosomes for detection of acute kidney injury (AKI), which has a high 
mortality and morbidity rate [35-37]. Proteinuria reveals significant reduced fetuin in the 
blood sera and increased in urine [37]. Prostaglandin is proposed to be a sensitive indicator of 
renal damage (UniProt), if found in large amounts in urine and serum. Its formation depends 
on renin secretion, renal regulation of sodium chloride balance and the control of blood 
pressure [38-40]. Perlecan (basement membrane-specific heparan sulfate proteoglycan core 
protein HSPG2) has been found in urine of patients with end-stage renal disease and in the 
amniotic fluid of pregnant women with premature rupture of fetal membranes (UniProt). 
Alpha-1-microglobulin protein (AMBP) is found to be one of six proteins which were able to 
discriminate endemic nephropathy (EN) with low and high proteinuria (<150mg/l) and high 
significance [36]. Serum albumin is a typical blood system protein and increased amount is a 
strong sign for kidney failure [36,41]. 
 
4.4.2.2 ECM-related proteins 
 
We found a number of ECM-associated proteins: perlecan, agrin, collagen IV, biglycan, 
hemicentin and fibronectin. These proteins are all involved in ECM-assembly and thus in 
basement membrane assembly. Except collagen IV, all of them are N-glycosylated [42]. 
Glomerulus endothelial cells contribute importantly to the assembly of the glomerulus 
basement membrane (GBM) [43] 
If N-glycosylation is changed, we probably have an influence on the basement membrane 
assembly of the glomerulus, thus we can expect disturbed cell adhesion and a heightened 
permeability of the filtration network, the clinical picture of renal failure.  
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4.4.3 Identification of exosomal raft proteins by LC-ESI of SDS-gel fractions 
 
Exosomal lipid rafts were separated by gel-electrophoreses and four selected coomassie-
stained gel fractions were excised (Fig. 33 Attm. p.87). Only gel fractions were excised that 
showed differences between galactosemic patients and controls. The LC-ESI-MS analysis 
revealed a large overlap with the iTRAQ data, but also identified a couple of proteins that had 
not been found in the differential approach (Fig. 29 Attm. p.83 yellow): The renin receptor, 
acid ceramidase, ladinin (an IgA binding protein), robo4,  VP37B (a vacuolar sorting protein), 
 CHM2A (a charged multivesicular body protein),  RhoA (validated by WB as well), ARF1, 
tetranectin, RAC1, RAP1A, arylsulfatase, matrix-remodelling-associated protein 8, 
transgelin-2 and kallikrein to name some.  
Obviously, the LS-ESI-MS analysis offers a higher sensitivity compared to the offline LC-
MALDI approach, which however is the only applicable one in the context of iTRAQ-
labelled peptides based on the equipment of the CMMC facility. 
The aim of using the complementary LC-ESI technique was to recognize qualitative 
differences between galactosemia and healthy persons by comparing the protein pattern, to 
excise them from Coomassie-stained gel and identify them by LC-ESI after extraction out of 
the gel slices. 
The top scores found by Mascot Search are perlecan (basement membrane-specific heparan 
sulfate proteoglycan core protein (PGBM)), serum albumin, tetranectin and inter-alpha-
trypsin inhibitor heavy chain H4 (Fig. 29 Attm p.83). Supporting these results, perlecan was 
found to be more abundant via the iTRAQ experiment (6.4 fold, Tab. 4c p.92). It emphasizes 
again the essential and disturbed function of basement membrane assembly in galactosemia. 
The loss of perlecan at the glomerulus is probably associated with a decreased retention 
capacity and renal failure that is supposed to occur prematurely.  
Serum albumin, the proteinuria marker, was found to have a high Mascot Score as well. The 
iTRAQ experiment offered a 4.8 fold abundance of the protein. Serum albumin is described 
for both a marker for insufficient glomerulus filtration and an overloaded protein dependent 
on reabsorbation process (megalin-cubilin-complex) [23].  
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5. Discussion 
5.1 A multitude of N-glycosylated proteins 
 
The reason for finding such a great number of N-glycosylated proteins is probably that the 
origin of exosomes are membranous cellular lipid rafts and that membrane proteins often 
carry carbohydrate branches exposed to the extracellular space. A closer look at the exosomal 
membrane (EM Fig. 13 p.37 / zoom 85000 X) reveals that the exosomal surface is 
comparable to epithelial surface that exhibits the characteristic glycocalix surface surrounding 
the membrane. Conclusively many glycoproteins were exposed at the exosomal surface. 
Surface exposition and secretion of glycoproteins is a defence mechanism of epithelial cells 
that prevents bacterial contamination of the urinary system or the bloodstream in E.coli-sepsis 
[44]. Obviously disglycosylation could lead to failure of the defence mechanism against 
bacterial infiltration. 
We determined a probable interdependence between N-glycosylation and increased protein 
amount. On the one hand, most of the detected N-glycosylated proteins are found in more 
than twofold amounts and, on the other hand, most of these proteins carry N-glycans. 
Surprisingly, high amounts of immunoglobulins were detected. Their respective amounts are 
increased more than twofold in galactosemia, and they mostly bear N-glycosylation. This 
elevation gravely hints at the clinical picture of renal failure, because serum proteins are not 
typical urinary proteins. Four most relevant diseases out of a multitude of renal failure 
diseases are related to this clinical picture: thin basement membrane nephropathy, IgA-
nephropathy (IgAN) [45], acute kidney injury (AKI) [35] and proteinuria [41]. The UniProt 
database presents exemplary clinical symptoms as followed: kidney injury, renal damage, 
inflammation, dementia, amyloidosis, loss of myelin, GM1-gangliosidosis. All these 
symptoms are closely connected to galactosemia.  
The normal size of filtrated molecules by the glomerulus is 6-15kDa. The intact glomerulus is 
impermeable for proteins greater than 80kDa, even for immunoglobulins, especially those that 
build di- and pentamers. The increased amount of immunoglobulins (Igs) that are found in 
Tab. 4c p.92 (disease associated proteins), lead to the assumption of an existing renal damage 
in galactosemic patients. An inflammatory response is possibly the cause of this damage. In 
IgAN, the IgA is embedded in the mesangial cells of the glomerulus that leads to 
inflammation [45]. Because of a defect in O-glycosylation (reduced glycosylation) the Igs 
adhere at the cell surface, they are not retained as usual due to their bulky carbohydrate 
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branches. Moreover, the disglycosylation leads to host recognition of the autoimmune system, 
and proinflammatory cytokine response. 
Albumin (66-69kDa) exhibits a filtration coefficient of 0,001 and 96% of the protein, which 
passes the filter, is reabsorbed at the proximal tubulus. More abundant amounts of albumin in 
urine are related to an enlarged glomerulus pore coinciding with an overloaded reabsorbation 
process. 
The reabsorbation process is ATP dependent and initiated by a megalin-cubilin-complex [23]. 
Both complex proteins were detected with top scores in the list of exosome associated 
proteins (Tab. 4b p.91). Cubilin, a membrane anchored protein, is able to interact with 
transferrin, apolipoprotein, albumin, Ig light chains and megalin. The transmembrane receptor 
protein megalin interacts even more strongly with lysozyme, amylase, epidermal growth 
factor, α-1-microglobin (AMBP) and retinol binding protein for instance; those all were listed 
proteins in Table 4. Megalin (LRP2) is a LDL receptor, the C-terminus is believed to mediate 
endocytosis and apical sorting [23]. The endocytic pathway initiated by the megalin-cubilin-
complex is proposed to be clathrin dependent.  
 
5.2 Disglycosylation and targeting of glycoproteins  
 
Evidence that the sorting for targeted trafficking of membrane glycoproteins to the apical 
plasma membrane is under partial control of N- and/or O-glycosylation has recently been 
provided [7]. Accordingly, it can be postulated that the expression of glycosylated receptors, 
like the epithelial growth factor receptor, EGFR, in membrane rafts requires specific glycan 
signals for (galectin-mediated [46]) entrapment in specific rafts [47]. A disglycosylation 
should have impact on these sorting and trafficking events and could result in a 
mislocalization of prominent membrane receptors with concomitant perturbations in the 
cellular signaling [48]. In a cellular model of GALT deficiency it has been shown that EGFR 
is actually lacking in lipid rafts, when the cells are grown under galactose stress (Fig. 30 
Attm. p.84) [49].  
Disglycosylation possibly affects basement membrane assembly. The nephridial glomerulus 
for example, needs correct basement membrane assembly to develop its full filtration 
capacity. For the correct assembly many glycoproteins interact stepwise to build up a 
network: perlecan, agrin, nidogen, fibronectin to name some (Fig. 34 see next p.) [42].  
 
 52 
 
 
If the network is disturbed, possibly by disglycosylation, renal failure could be the 
consequence. In principal all epithelial cells that are layered on basement membranes could be 
affected. It is imaginable that the assembly of the blood-brain barrier is disturbed, resulting in 
neurological degeneration. In galactosemia however, these disassembly processes, probably 
occur prenatally. The clinical picture of treated galactosemia does not exhibit deterioration of 
the patient’s state of health. 
It cannot be ruled out that other causes for the observed glycosylation shift are possible, i.e. 
disease-associated kidney insufficiencies that lead to secretion of complex-type serum 
glycoproteins [50] into urine and the partial association of these glycoproteins with exosomes 
as shown for fetuin and ceruloplasmin [35,45]. 
 
5.3 Secreted high-mannose-type glycoproteins probably do not recycle 
through the Golgi compartment   
 
Why does THP N-glycosylation not fluctuate in GALT deficiency as found on other 
membrane-integral N-glycoproteins in the urothelial membrane? It is known that THP is 
produced and shed from cellular membranes at high rates, which could imply that it passes the 
Golgi apparatus only once. We and others have demonstrated for single-passage 
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glycoproteins, like secreted isoforms of human MUC1, that these proteins preferentially carry  
high-mannose-type N-glycans compared to their membrane-tethered isoforms expressing 
more complex-type chains [51]. The latter often recycle after re-endocytosis through the 
Golgi compartments or the trans-Golgi network back to the plasma membrane [52], a process 
which could be accompanied by further processing of initially formed high-mannose-type to 
complex-type glycans.  
 
5.4 Criteria for Tamm-Horsfall Protein being membrane integrated or 
associated   
  
Because of the fact that THP is a cell surface protein, it is possible that the protein is not only 
secreted into the extracellular space, rather more it might be integrated into the membrane of 
the exosomes. The glycoprotein is integrated in lipid rafts at the plasma membrane of the cell 
surface and a part of it is perhaps endocytosed and sorted into vesicles for secretion, following 
the characteristic exosomal pathway. In comparison, Mucin-1 (MUC1) is a glycoprotein that 
either belongs to the exosomal secretion pathway (confirmed by WB, by the use of a MUC1- 
C-terminal cytosolic domain-specific antibody H295). A part of the membrane located protein 
is cleaved and shed extracellularly. After cleavage the cytosolic domain that travels by HSP 
interaction to the nucleus or mitochondria remains intracellular [53]. The fact that after 
PNGaseF digestion THP was still abundant is a reason for being integrated into the exosomal 
membrane. An antibody raised against the cytosolic domain of THP could eventually answer 
the question of the exact location of THP, whether it is membrane integrated or only adherent 
as a filamentous polymer. 
 
5.5 Galactosemia - a secondary dual congenital disorder of glycosylation 
(CDG) 
 
According to detected disglycosylation of exosomes disglycosylation of serum proteins could 
be expected. For example the FSH could be assumed to be dysglycosylated and that would 
give a reason for female infertility caused by galactosemia. But Gubbels et al. published that 
FSH isoform patterns do not favor FSH dysfunction due to hypoglycosylation as a mechanism 
in the pathophysiology of ovarian failure in classic galactosemia [5]. Referring to this normal 
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FSH bioactivity was measured in women with classic galactosemia [54] pointing to an 
ovarian insufficiency in galactosemia. Many publications found abnormal isoforms 
corresponding to reduced sialylation of carbohydrate branches but these are found in 
untreated galactosemic patients that are not on strict diet. In this special case transferrin, FSH, 
and lysosomal enzymes α-fucosidase and β-hexoasminidase are more neutral charged because 
of a lower degree of sialylation [6,55-57], transferrin is undergalactosylated, fucosylated to a 
higher extent and branched in N-glycosylation, but these abnormities found in galactosemic 
patients normalized upon dietary treatment [11]. Summarized the glycosylation affects 
characterize galactosemia as a secondary dual CDG with an assembly defect and a processing 
defect (secondary CDG-I/II) [11]. 
The glycans from normal transferrin consisted predominantly (86%) of the disialylated 
biantennary complex type [6] and serotransferrin is 2.7 fold more abundant, as found via the 
iTRAQ experiment (Tab. 4b p.91). The analysed complex-type shift could therefore be 
influenced by exosome adherent protein. 
 
6. Conclusion 
6.1 N-Glycan remodelling of high-mannose to complex-type 
 
It was demonstrated that a dysglycosylation of cellular membrane-bound proteins occurs in 
galactosemic subjects adhering to a galactose-restricted diet. Thus, it seems that aberrant 
glycosylation is a consequence of the relatively high amounts of endogenously synthesized 
galactose. The shift in expression from preferentially high-mannose-type to complex-type 
glycans reflects an increased processing rate in early Golgi compartments comprising three 
steps, the trimming by α-mannosidases I and II, the GlcNAc transfer by β-GlcNAc-
transferases GlcNAc-T I and –T II and the galactosylation by the β-4Gal-T. The complexity 
of the entire trimming and reglycosylation process lets it seem unlikely that only co-substrate 
levels of UDP-Gal, which may be altered in galactosemic patients, are the primary and direct 
cause of these dramatic changes. Other specific or global alterations on the proteomic level 
will have to be identified by differential proteomics. Severe cellular pathomechanistic effects 
can be expected to result from the described N-glycoprofile changes. As N-linked glycans 
form signals in the sorting for targeted traffic of membranous glycoproteins, profound effects 
on the (apical) membrane localization and function of glycosylated receptors in lipid rafts can 
be expected.  
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6.2 Clinical pictures of renal failure 
 
The differential proteomics of exosomal lipid rafts in galactosemia revealed protein changes 
corresponding to the clinical picture of renal kidney failure or damage. Because we selected 
samples that showed strong N-glycosylation shifts from high-mannose to complex-type N-
glycosylation, the results of differential glycomics could be affected strongly by N-
glycoproteins associated with kidney failure. At this state of research we can only hypothesize 
that renal failure is caused by premature protein dysglycosylation leading to disturbed 
basement assembly. We were not able to conclude whether the actually detected shift was a 
result of serum proteins passed through the filtration apparatus, or if we identified a chronic 
intracellular dysglycosylation process. 
We found four clinical pictures with strong overlap concerning the more abundant proteins:              
1. IgAN    2. TBMN   3.  Proteinuria   4.  AKI 
Almost all marker proteins that distinguish between IgAN and TBMN [45] are found to be 
more abundant in our study, thus we were not able to differentiate between both clinical 
pictures applied to galactosemia. There appears to be a closer relationship to IgAN, because 
the more abundant markers are those characterizing IgAN. In comparison, especially the 
slightly decreased amounts of MVB proteins and the markedly down-regulated galectin-3-
binding-protein were found in both studies. Markers identified by Moon for TBMN were: 
aminopeptidase N, vasorin, α-1-antitrypsin and ceruplasmin. The marker proteins chosen by 
Moon were all found in our study to be markedly increased.  
At this stage we were not able to distinguish whether the N-glycosylation shift is caused by an 
intracellular change in the glycosylation machinery or by serum proteins passing the disturbed 
filtration apparatus of the glomerulus. 
 
6.3 Reasons for detecting serum proteins in urine 
 
There are two main reasons for detecting high levels of serum protein in urine. 
Firstly, galactosemia induces renal failure, a condition during which the glomerulus will not 
efficiently filter proteins out of urine. Secondly, the reabsorption efficiency of proteins 
passing through the proximal tubulus is thought to be diminished. It is known from previous 
studies that glycoproteins of the blood serum, e.g. transferrin, bear complex-type N-
glycosylation. It is possible that these glycoproteins stick together with glycoproteins at the 
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surface of the exosomal lipid rafts and that the elevation of these sticky glycoproteins in 
exosomal membranes results in the observed N-glycosylation shift from high mannose to 
complex-type. The kind of detergent (Triton X-100) and the amount implemented was 
probably not sufficient to prevent “stickiness” between N-glycans of glycoproteins in urine 
and of exosomal lipid rafts. 
The exosomes were purified in high quality using modified published methods and the shift 
may belong to the glycoproteins that are integrated and strongly associated with the 
membrane. If so we detect the actual glycosylation shift of the exosomal glycoproteom. In 
Western blot was shown that MUC1 for example exhibits a glycosylation shift in 
galactosemia, it runs slower in galactosemia than in control person (Fig. 31 Attm. p.85). 
MUC1 carries high-mannose-glycosylation under healthy conditions and not complex type. In 
Western blot and in the iTRAQ experiment (Tab. 4a p.90) we found that the amount of 
MUC1 in exosomal protein seems to be very constant.  
6.4 Hypergalactosylation in samples from galactosemia patients 
 
O-glycosylation of the exosomal glycome was examined twice and compared with each other. 
Mass spectrometry could not reveal any differences in o-glycosylation pattern. We expected 
to detect undergalactosylation of the glycoproteins [11], but undergalactosylation was not 
detectable. Classic galactosemia patients have a low UDP-galactose/UDP-glucose ratio [58], 
in addition a UDP-hexose deficit was found [59]. Via mass spectrometry we found the 
phenomenon of less undergalactosylated species in galactosemia. This contradicts previous 
observations [60]. If serum proteins are only responsible for the complex-type shift, 
theoretically they should cause a shift to hypogalactosylation. But the opposite was detected: 
hypergalactosylation of N-glycans in samples from galactosemic patients in comparison to 
those of healthy persons. 
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6.5 Hypertension in combination with renal failure is dangerous in 
galactosemia 
 
We cannot corroborate which theory is applicable at this state. Either the glycosylation shift is 
caused by adherent serum glycoproteins or integrated exosomal proteins. In future 
experiments we can check the N-glycosylation of the supernatant glycome in comparison to 
the exosomal and can than distinguish if the shift is caused by protein not correctly filtered or 
by protein only found on and in exosomes. 
However the results may be, we were able to detect a direct relation to the N-glycosylation 
shift found in galactosemia, correspondent to renal failure. Furthermore we identified an 
expanded list of abundant typical marker proteins detectable in proteinuria and renal failure. 
Summarized, the N-glycosylation shift is a strong predictor for galactosemia patients to get or 
with higher probability to have got renal failure. For that reason it is not necessary to make a 
biopsy of the kidney anymore to clarify the state of the kidney filter function. 
Galactosemia patients on diet are able to live in normal fashion, but hypertension in 
combination to this clinical picture of kidney dysfunction is dangerous. The findings strongly 
suggest regular check-ups of hypertension in galactosemia. Hypertension could lead to 
enlargement of the filtration cut-off causing excess loss of serum proteins and non-reversible 
damage of the glomerulus. 
We can not conclude at this moment if the dysglycosylation chronically affects the thin 
basement membrane of the glomerulus, and in concordance we found exosomal 
dysglycosylation. Maybe because of renal failure we found increased amounts of serum 
proteins (e.g.: Immunoglobulins / Igs) in the urine that caused the glycosylation shift.  
To validate the results, a second iTRAQ analysis is necessary, again divided in at least two 
galactosemia patient samples and two controls. If the results were in accordance and exhibit 
the same clinical picture, and the results were validated by Western blot a second time we 
assume with high certainty that the found exosomal N-glycosylation shift is related to chronic 
renal failure. 
Methodologically iTRAQ is a valuable form to compare quantitative content and regulation of 
exosomes. To detect all proteins without regarding to the regulation the sample analyzation 
using LC-ESI after gel electrophoreses, Coomassie staining, cutting gel slices and protein 
digestion is able to raise the amount of detecting proteins. Thus it seems to present a 
reasonable additive extension for whole proteome detection. 
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7. Future experiments: Glycolipid analysis of urinary exosomes 
 
In future experiments it will be most interesting to analyse glycolipids of urinary exosomes. 
Using classical lipid extraction methods they could be isolated in high purity and potentially 
sticking serum proteins could be detached easily to reveal significant alteration in lipids and 
glycosylation. 
These lipids as well as their glycan part could by qualitively and quantitatively analysed [61]. 
A preceding impressive study of lipid alteration in galactosemia brain ascertained: 
“Galactosylceramide appeared to be reduced about 3-fold in the galactosemic brain when 
compared to the two controls. Furthermore, there was a 3- to 4-fold increase in the amount of 
glucosylceramide in the galactosemic sample. This is to be expected since glucosylceramide 
is next substituted by galactose from the UDP-Gal donor to form lactosylceramide and, with 
UDP-Gal being limiting, the precursor, glucosylceramide, will accumulate. Finally, the 
alteration observed for each lipid leads to a l0-fold reduction in the ratio of 
galactosylceramide/glucosylceramide in the galactosemic brain” [62]. Differences in vesicle 
lipid composition and glycosylation probably will give indirect hints to brain lipid alteration. 
Additionally it is easier to retrieve samples from living persons for the generation of urinary 
exosomes instead of being dependent on organ donation. 
In accordance with the reported findings above and their hypothetical implications we are 
currently performing a differential proteomic study based on the GALT-deficient fibroblast 
cell model (grown under galactose-free and under galactose stress conditions) to reveal 
insight into changes of the lipid raft (glyco) proteomes. These analyses will hopefully give 
insight into cellular changes and pathomechanisms induced by endogenous galactose-stress 
via protein disglycosylation. 
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9. Legends to attached figures 
 
Fig. 2 (p.68) 
Mislinkage of arginine 188 
Mislinkage of the hydrogen bond from the upper phosphoryl groups (O2A/O1B) to the lower 
situated hydrogen bond types (O5´/O2B) dependent on the amino acid exchange Q188R. The 
mislinkage drastically reduces the enzymatic turnover rate. 
 
Fig. 3 (p.69) 
Bulky residue of arginine disturbs dimeric close up of subunits and active sites 
The bulky arginine residue exhibits a longer side chain in comparison to glutamine and 
therefore causes a destabilization effect. It negatively influences the substrate fitting to the 
surrounding hydrophobic pocket of the active site. 
 
Fig. 4 (p.70) 
Ping-Pong double displacement reaction of GALT 
The first substrate UDP-glucose in composition with GALT binds to the active site that forms 
the intermediate complex GALT-UDP-glucose. It is subsequently cleaved to GALT-UMP. It 
remains attached to the enzyme in complex. Glucose-1-phosphate the first product that is 
released (“ping-reaction”). The second (co-)substrate added is galactose-1-phosphate that 
forms the second intermediate complex GALT-UDP-galactose with GALT-UMP. During the 
final step the second product UDP-Galactose is released by the enzyme (“pong-reaction”) and 
the GALT is ready to take part in another turnover cycle. 
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Fig. 8 (p.71) 
Glycoprotein travelling via lipid rafts 
Lipid raft endocytosis takes place in two different ways: (1) via the caveolin and dynamin 
dependent manner or (2) via flotillin (a scaffold protein); in this case dynamin independent. 
MUC1 is a membrane-bound glycoprotein which travels inside these lipid raft originated 
vesicles to the early endosomes (E). It then recycles through the trans-Golgi network (TGN) 
and a recycling endosome (RE) back to the cell surface. 
A further possibility is that re-endocytosed membrane glycoproteins are sorted into exosomes 
for cellular export (4). If the glycoprotein is not targeted to the lysosome (Lys) the endosome 
converts to a MVB that proceeds to fuse with the membrane and secretes the exosomes into 
the extracellular space. 
 
Fig. 12 (p.72) 
N-glycosylation exosomes 
Glycoproteins located at the exosomal surface were digested by PNGaseF subsequently the 
N-glycans were purified over C18 column, methylated and analyzed by mass spectrometry. 
 
Fig. 14 (p.73) 
Western blot of exosomal marker proteins separated by continuous gradient 
centrifugation 
Western blot of fractions from density gradient centrifugation of urinary exovesicles, 
demonstrating the presence of exosomal markers preferentially in the high-density fraction 5 
(MUC1, mucin-1; Alix, apoptosis-linked gene-2 interacting protein X; hsp70, heat-shock 
protein 70; Flot-2, flotillin-2; Gi , G protein subunit ; hsp27, heat-shock protein 27. 
 
Fig. 15 (p.74) 
Tamm-Horsfall protein contamination of urinary exosomal vesicles (Coomassie stain) 
Representative Coomassie-stained SDS-polyacrylamide gels of exovesicular preparations 
from a galactosemia patient (lane 1) and two controls c1 and c2 (lanes 2 and 3) showing the 
presence of  THP as a major protein. 
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Fig. 16 (p.75) 
Filtration of exosomes (0.1µm filter) 
The Electron microscopy (85000 X) picture of 100nm filtered exosomes exhibits fragmented 
exosomal structures. The mechanical shearing force by filtration leads to lysation and 
fragmentation of exosomes. 
 
Fig. 19 (p.76) 
High-mannose (left) versus complex-type (right) species detected by mass spectrometry.  
Five high-mannose- and six complex-type structures were mainly detectable. The high-
mannose-type N-glycans varied between four and eight terminal mannoses (Fig. 19/left side) 
The complex-type mainly varied between six different structures: four species exemplary for 
the biantennary species with GlcNAc-Gal added to the corestructure that could be single- or 
double sialylated, with both structures fucosylated or non-fucosylated, respectively. The tetra-
antennary structure was identified as double sialylated and tetra sialylated species (Fig. 
19/right side). Many undergalactosylated species were detected for the bi- and tetra-antennary 
carbohydrate branches, but they were not considered for the calculation of the shift (example: 
Fig.19/right side below). If they were added, the result would be more intense than already 
detected. 
 
Fig. 23 (p.77) 
DTT to remove THP from exosomes  
Coomassie stained exosomal proteins separated in 1DE. Membranous samples were incubated 
with DTT collected by ultracentrifugation and prepared with Laemmli-SDS-buffer for 1DE. 
DTT 200mg/ml at 37°C, 10min, was used to remove THP from whole exosomes and 
exosomal lipid rafts. Three lanes at the left side: fresh isolated exosomal samples of a healthy 
control, three lanes at the right side: samples of a galactosemia patient after storage of a 
period of some weeks (-20°C).  
High amounts of THP were visible in both untreated samples (lane 1 and 4). The DTT treated 
samples (lines 2 and 5) show a loss, but a lot of THP remains. The exosomal lipid rafts (lines 
3 and 6) still exhibit a lot of THP after DTT incubation and an additional TritonX-100 
incubation step for the generation of rafts. DTT could not be used to completely remove THP, 
rather reduces the amount slightly. The THP amount does not markedly depend on preparing 
the sample fresh or using a thawed one. Both samples, whether from healthy person or from 
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galactosemia patients, contained THP and it adhered strongly to the exosomes. Unfortunately 
the total intensity of the protein pattern weakens either after DTT treatment. 
 
Fig. 24, 25 (p.78/79) 
Representative MALDI mass spectra of permethylated N-glycans from urinary THP of 
GALT-deficient patients and healthy control subjects 
A, Representative MALDI mass spectrum of permethylated N-glycans liberated from 
electrophoretically purified THP contaminating the exovesicular preparation of a 
galactosemic patient; B, the respective sample from a healthy control subject. STD refers to 
the internal standard LNFPI. 
 
Fig. 26 (p.80) 
Coomassie stained 1D gel-electrophoreses  
An aliquot of the exosomal lipid raft extracted proteins (15µg) was applied on a gradient 1D-
gel (5-15 %). The gel-electrophoreses was done for visually examination of the protein 
pattern after precipitation (chloroform/methanol) of the samples previous to the iTRAQ 
application. 
The first two lanes represent two different samples of galactosemia patients and the last two 
lanes two control persons. The protein pattern of both galactosemia patients is comparable 
just as well as the pattern of both control persons. The protein pattern of galactosemia patients 
and control persons in contrast is strikingly distinct.  
 
Fig. 27 (p.81) 
Validation of up and down regulated proteins by Western blot 
Three elected proteins one of them was found to be increased one decreased (see results of the 
iTRAQ experiment) and one constant were compared by Western blot. In concordance to the 
detected regulation of proteins by iTRAQ, the CD81 tetraspanin a characteristically exosomal 
marker protein was upregulated in galactosemia (lane 1 and 2). In contrast the exosomal 
marker Alix was markedly down regulated in galactosemia (lane 3 and 4). MUC1 was 
recognized in several Western blots to be expressed in nearly constant quantities regardless 
which sample was applied (galactosemia patient or healthy person). 
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Fig. 28 (p.82) 
THP identification 
Four different samples of coomassie stained 1D gel-electrophoretically separated proteins 
(15µg/lane) of exosomal lipid rafts. The THP mass is equal in galactosemia- and control-
samples and is typically found between 75 and 100kDa after 1DE. One band of the control 1 
was excised, protein digested, analyzed by LC-ESI and identified by the mascot search 
database. The most dominant found protein was as expected uromodelin (Fig. 32 p.86) mascot 
search result). 
 
Fig. 29 (p.83) 
Mascot Search results after LC-ESI analyzation 
The identified proteins were sorted into equal subclasses according to the iTRAQ tables. The 
identified proteins exhibit semantic overlaps (see iTRAQ) but additional proteins were found 
that expand the list of proteins detected by the iTRAQ method. Additional detected proteins 
were highlighted in yellow. 
 
Fig. 30 (p.84) 
EGFR expression in healthy and diseased fibroblasts    
Westernblot EGFR with house keeping protein under different sugar addition to the cell 
culture supernatant (30µg protein / lane) 
Left side: Healthy fibroblasts (FibH) were incubated for 48h with 0.1 % galactose (five lanes 
left) or 0.1 % glucose (five lanes right). α-Tubulin was used as house keeping protein. 
Independent of the added sugar, a relative high amount of EGFR expression was found. 
Right side: Healthy fibroblasts (FibH) and GALT deficient fibroblasts (FibQ) were grown 
under high glucose level. Caveolin-1 was used as house keeping protein. 
Independent of the constant sugar amount, but dependent on cell type, the EGFR was detected 
in healthy fibroblasts but was nearly absent in GALT deficient fibroblasts (FibQ). 
 
Fig. 31 (p.85) 
Glycosylation shift of MUC1 detected by Western blot 
Exosomal MUC1 of galactosemia patients runs higher in 1DE than MUC1 of healthy 
controls. Different causes could explain this phenomenon. Shorter carbohydrate branches, a 
glycosylation shift from high-mannose to complex-type or charge alterations caused by 
sialylation or SDS binding. 
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Fig. 32 (p.86) 
Mascot search result 
THP (uromodelin) was identified by the top score of 1180, followed by galectin-3-binding 
protein 402 and three further proteins under the off cut of 100. THP was validated to be the 
high abundant protein that was found in exosomal samples. 
 
Fig. 33 (p.87) 
1DE of exosomal lipid rafts (Coomassie stained) for LC-ESI-MS-MS analyzation 
An aliquot of the exosomal lipid raft extracted proteins was applied on a gradient 1D-gel (5-
20%). The first two lanes represent the glycosylation pattern of two different galactosemia 
patients and the last two lanes two controls. Visually detected different protein bands of the 
second galactosemia patient were excised and analyzed after extraction by LC-ESI. One 
diverging protein was found to be most dominant in galactosemia: Perlecan  
(PGBM_Human / Basement membrane-specific heparin sulphate proteoglycan core protein).  
 
10. Legends to supplements 
 
Suppl. Tab.1 (p.88) 
THP variation of samples were previously visualized by 1DE Coomassie stain and afterwards 
used for N-glycan analytic. Ratio of complex- to high-mannose-type glycans in exosome 
samples with high or low THP content. The presence of THP in exovesicular preparations 
however did not strongly influence the ratios of complex- vs. high-mannose-type glycans in 
samples with high or low THP content. 
 
Suppl. Tab.2 (p.89) 
Variation between independent urine samples from one healthy control. 
The variations of ratios (complex-type vs. high-mannose-type glycans) measured for 
independent urine samples from individual healthy control subjects were only small. 
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12. Kurzzusammenfassung 
 
Die klassische Galaktosämie wird durch eine defiziente Transferase verursacht, die Glaktose-
1-phosphat-Uridyltransferase (GALT). Ursache dieser Defizienz ist eine genetisch vererbte 
Mutation, die einen Aminosäureaustausch am aktiven Zentrum des Enzyms bewirkt. Die 
Wechselrate des Enzyms wird hierdurch um mehr als das Tausendfache reduziert. Exogene 
Galaktoseaufnahme insbesondere aus Milchprodukten induziert eine intrazelluläre 
Stressantwort. Das Co-Substrat der GALT, Galaktose-1-phosphat akkumuliert in der Zelle, 
beeinträchtigt den Zuckerstoffwechsel und wahrscheinlich den Leloir-Galaktosestoffwechsel. 
Der Leloir-Galaktosestoffwechsel stellt UDP-Galaktose und UDP-Glukose für die 
Glykosylierung von Proteinen und Lipiden bereit. Die UDP-Galaktose wird beispielsweise für 
die Synthese von N-Glykoproteinen des Complex-Typs benötigt. Es wurde angenommen, dass 
wenn der Leloir-Galaktosestoffwechesel beeinträchtigt ist, dies auch in der Galaktosylierung 
der Complex-Typ Glykane wiederzufinden sein wird. Um diese Veränderungen in 
Glykosylierungsmustern wiederzufinden, erwies sich die massenspektrometrische 
Glykananalyse als besonders aussagekräftig. Mithilfe des enzymatischen Verdaus durch 
PNGaseF konnten die N-Glykane von den Glykoproteinen abgelöst werden und anschließend, 
nach erfolgter Methylierung, unter Anwendung von Matrix Assisted Laser 
Desorption/Ionization Massenspektrometrie, vermessen werden. Um Veränderungen der 
Glykosylierungsmuster zu detektieren haben wir Vesikel aus dem Urin von 
Galaktosemiepatienten isoliert und die N-Glykosylierung der hier lokalisierten Glykoproteine 
mit denen von gesunden Kontollpersonen verglichen. Wir konnten zeigen, dass es sich bei 
den Vesikeln zum größten Teil um Exosomen handelt. Der Vergleich der Massenspektren 
ergab einen dramatischen N-Glykosylierungsshift von dem in gesunden Personen 
vorherrschenden High-mannose-Typ zum Complex-Typ. Der angenäherte Wert des 
Verhältnisses von High-mannose-Typ zu Complex-Typ Glykanen bei gesunden 
Kontrollpersonen betrug 3:1. Insbesondere die N-Glykane, bestehend aus fünf oder sechs 
Mannosen, waren in auffällig erhöhter Menge zu finden. Im Gegensatz hierzu veränderte sich 
die Mengenverteilung bei Galaktosämiepatienten in Richtung 1:1 zum Complex-Typ. Die 
meist vorhandene Struktur, die bei Galaktosämiepatienten auf Exovesikeln zu finden war, 
entsprach einem Complex-Typ Glykan mit einer bi-antennaren Struktur, die endständig 
disialyliert war und keine Kern-Fukose trug. Glykane, die eine höhere Verzweigung 
aufwiesen, konnten nur in sehr geringen Mengen detektiert werden. Der beobachtete 
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Glykosylierungsshift ist als neuer Befund einzuordnen, denn bislang konnte eine veränderte 
Glykosylierung nur unter akutem Stress bei sekretierten Proteinen wie dem Transferrin 
festgestellt werden. Wenn diese Veränderung wie gezeigt membranäre Proteine betrifft, ist 
anzunehmen, dass auch glykosylierte Rezeptoren von diesem Ereignis betroffen sind. 
Veränderungen der Glykosylierungen können für eine Mislokalisation von Glykoproteinen 
verantwortlich sein, insbesondere könnte dies zutreffen für Glyko-Rezeptoren, wie dem 
EGFR (epidermal growth factor receptor), der üblicherweise auf der apikalen Seite von 
epithelialen Zellen exponiert wird. 
Quantitative und qualitative Veränderungen membrangebundener exosomaler Glykoproteine 
geben indirekt Auskunft über die Veränderungen auf der zellulären Membran. Wir konnten in 
Westernblots zeigen, dass die erhöhte Menge an EGFR, die in exosomale lipid rafts sortiert 
wird, korreliert, mit einer reduzierten Menge an EGFR in den plasmamembranären lipid rafts. 
Um die Veränderungen des Glykoproteoms insbesondere von Glykorezeptoren in exosomalen 
lipid rafts festzustellen, war eine Quantifizierung durch Labeling mit isobarischen Tags zur 
relativen und absoluten Quantifizierung (iTraq) sehr nützlich. Vier einzelne Proben von vier 
Individuen wurden hierzu ausgewählt: Zwei Proben von Galaktosämiepatienten und zwei 
gesunde Kontrollpersonen. Die beiden Proben der Galaktosmiepatienten zeigten den 
typischen Glykosylierungsschift von High-mannose zum Complex-Typ der vorangegangenen 
Studie. Die Proben wurden mit den isobaren Tags versehen, danach vereinigt und 
anschließend über nano-LC MALDI-MS/MS analysiert. Obwohl kein EGFR gefunden 
werden konnte, wurden erhöhte Mengen an N-Glykoproteinen und einigen Rezeptoren 
gefunden, die exosomenassoziiert vorlagen: Der Tyrosin-Proteinkinase-Rezeptor UFO, zinc-
alpha-2-glycoprotein (ZA2G, MHC I–Familie) und Aminopeptidase N (CD13) sind hier zu 
nennen. Der Cubilin- und Megalin-Rezeptor wurden detektiert. Beide dimerisieren und 
formen einen Megalin-Cubilin-Komplex der für die Rückresorption von Proteinen aus dem 
proximalen Tubulus der Nephridien zuständig ist. Dieser Cubilinrezeptor wurde bereits in 
einem vorangegangenen Experiment als auffälligster Unterschied zwischen Proben von 
Galaktosämiepatienten und Kontrollpersonen festgestellt. Letztendlich wurde ein weiteres 
unerwartetes Ergebnis mittels iTRAQ-Methode ausgemacht. Die  Proben der 
Galaktosämiepatienten enthalten stark angereicherte Mengen an Serumproteinen, besonders 
N-glykosylierte Serumproteine. Eine Vielzahl an Immunglobulinen waren erhöht, desweiteren 
Albumin, Fetuin, Transferrin und viele mehr. Zusammengenommen weisen diese Ergebnisse 
auf das Krankheitsbild einer Niereninsuffizienz bei Galaktosämie hin. 
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Die übliche Methode um diesen Befund festzustellen war in der Vergangenheit die 
Organbiopsie. Die Untersuchung urinärer Exosomen, könnte in diesem Kontext eine 
innovative Methode darstellen, um ohne körperlichen Eingriff Nierenversagen feststellen zu 
können. 
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